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INTRODUCTION 
Scrub typhus is a zoonotic bacterial infection, which is a chigger borne rickettsiosis. It 
is an important cause of acute febrile illness in South East Asia and South Western 
Pacific regions(1).It is a reemerging  bacterial infection. The causative bacterium, 
Orientia tsutsugamushi is transmitted to humans and rodent hosts by the bite of the 
larval stage of trombiculid mites (Vector) Leptotrombidium deliensis called chiggers. 
The Vector is seen in a wide variety of ecological regions from the mountainous 
regions of northern India to the tropical climates of the Malay Peninsula, and 
Indonesia. The clinical features include acute presentation of fever, myalgia, 
headache, Mutiple organ dysfunction with an eschar at the site of inoculation in 
variable proportion of patients(2).It can range in severity from a mild disease, self 
remitting disease to a  fatal illness with 30-50% mortality(3) if untreated in earlier 
studies and 7.8-9% noted in recent data(2,4). World health organization (WHO) has 
declared it a re-emerging disease and has called for increased surveillance. They can 
have an elevated hepatic enzymes, creatinine, and bilirubin. They may have 
thrombocytopenia, leucopenia or leukocytosis. It can be confirmed using serology 
using the indirect fluorescent antibody assay, biopsy of the eschar, culture and 
polymerase chain reaction on the tissue, eschar and serum(5). 
Scrub typhus is diagnosed based on clinical evidence and appropriate laboratory 
features. There is no laboratory test that is reliable in the early stage of the disease. 
Scrub typhus lasts for 14 to 21 days without therapy. Death may occur in the late 
second week due to the complications(6). Patients treated with appropriate therapy 
show fever defervescence within 48 hours after the initiation of the therapy, this 
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response is considered characteristic for diagnosis of scrub typhus. The various groups 
of antimicrobials used are tetracycline (Doxycycline), macrolides (Azithromycin), 
Chloramphenicol. Failure of defervescence within 48 hours is suggestive of an 
alternative diagnosis for the acute febrile illness. However it has been noted in the 
recent studies to have a delay in the defervescence duration with appropriate therapy. 
In a study done in 2004 showed that 20 of the 93 patients had a delay in defervescence 
in the fever duration beyond 48 hours(7). A retrospective study from china in 2008 
showed that 18 out of 88 patients had a delay in fever defervescence beyond 48 
hours(8).  The above said studies assessed the role of therapy in mild disease with no 
studies in patients with severe disease. The proposed studies aims to study the various 
antibiotics used, incidence of delayed defervescence and the factors affecting the 
same. 
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AIM 
 
To study the factors associated with outcome and comparison of antibiotic regimens in 
the treatment of scrub typhus. 
 
 
OBJECTIVES 
 
1. To find the incidence of delayed defervescence in all scrub typhus patients. 
2. To determine and compare the different antibiotics used for the treatment of 
scrub typhus. 
3. To determine the factors associated with delayed fever defervescence.  
4. To determine the pattern of resolution of organ involvement in patients with 
severe scrub typhus with multi-organ dysfunction. 
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LITERATURE REVIEW 
 
 
Scrub typhus is a mite borne infectious disease caused by Orientia tsutsugamushi. The 
disease was described by the Chinese in the third century but the first descriptions 
were seen in the western literature in the nineteenth century. Knowledge about scrub 
typhus increased in the Second World War era when the soldiers had a common 
occurrence in the pacific fight mainly in the Vietnam and the indo china border. 
 
HISTORY 
Scrub typhus has been described by Chinese investigators since third century A.D. It 
was first reported by Hashimoto in 1810 in Japan as a life threatening disease 
occurring in the northern island of Honshu along the river banks(9). The Japanese 
associated the disease with bite of a jungle mite named tsutsugamushi which is for 
dangerous bug in Japanese. Heterophile antibody for scrub typhus was first 
demonstrated by Fletcher and Lesslar in 1926. The causative organism was first 
isolated in 1931 by Ogata and was named by which it is known today, Orientia 
tsutsugamushi in1996(10).The disease was associated with altered sensorium(typos 
for fever with stupor in Greek) and was associated with scrub lands hence the name 
scrub typhus.  
Scrub typhus occurred in periodic outbreaks in the early 1900s, it was reclassified as 
typhus like illness fever in 1917. The disease had a very high case fatality rate 
approaching 50% in untreated cases causing thousands of deaths in the World War II 
era. The local name for the illness in Japan continues to be tsutsugamushi, with other 
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names being akamushi (red mite) fever and kedani (hairy mite) fever also noted. The 
resurgence of scrub typhus is seen in various parts of India and neighbouring 
countries. 
 
EPIDEMIOLOGY 
 
Organism: 
Scrub typhus is caused by O. Tsutsugamushi. It is a gram negative obligate 
intracellular bacterium. 
It was earlier classified under genus Rickettsia based on the following characteristics 
shared with the other members of the genus 1) basic morphology, 2) exhibited 
obligatory intracellular parasitism, 3) required an arthropod for human transmission, 
4) ability to survive in both vertebrate and invertebrate host. However Tamura et al 
proposed it be reclassified under a new genus, Orientia based on several 
differentiating factors namely 1)16s RNA sequencing showed it to be different from 
other rickettsial, 2)electron microscopy showed a thicker outer leaflet of the cell wall 
with ill formed flagella and endospores, 3) lack of peptidoglycan and 
lipopolysaccharides, such as muramic acid, glucosamine, hydroxyl fatty acid, 2 keto 3 
deoxytonic acid, making the cell structure fragile and penicillin resistant, 4) gel 
electrophoresis showed abundance of major cell surface 56 KDa protein and 60 KDa 
protein, 5)growth in cell lines demonstrated phenomenon of budding similar to 
enveloped virus with absence of electron lucent halo zones around growing cells and 
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6) Heterophile antibodies to OXK antigens on the weil felix test. In 1996, genus 
Orientia was classified consisting of a single species Orientia tsutsugamushi(11). 
 
ENDEMICITY 
It is seen in the terrain areas of the ‘tsutsugamushi’ triangle which is a geographical 
region comprising South East Asia and Southwest Pacific (1). Scrub typhus was 
known as early as the 3rd century in China; however the magnitude of the disease was 
evident in the 2nd world war as many soldiers were victims of the chigger mite borne 
disease. 
 
Figure 1: “The Tsutsugamushi Triangle” 
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Though whole of India is reported to be endemic for the disease, the reporting of the 
disease has seen a recent surge since 2004 from different parts of the country. Scrub 
Typhus is mainly noted in areas which are scrubby and are forested, which are the 
usual reservoirs of rodents and mites (seen in figure below)(12). 
 
Figure 2: Endemicity of Scrub Typhus in India 
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MICROBIOLOGY 
The organism is a gram negative, Giemsa positive coccobacillus that is antigenically 
different from the Typhus group of Rickettsia. It measures 0.5-0.8µm X 1.2µm in size. 
It is surrounded by a cell wall around the cell membrane. The cell wall is made up of a 
major surface protein which is made up of a 56kDa substance comprising 10-15% 
proteins. The cell wall also has a 60kDa protein which is related to GroEL family of 
protein which is mainly seen in the eukaryotic bacteria. It does not have a slimy layer, 
flagella formation or sporulation. The cell wall does not have peptidoglycan or 
lipopolysaccharides such as muramic acid, glucosaminoglycans, and deoxytonic acid 
and hydroxyl fatty acid. 
There are more than 20 different antigenic strains of O. Tsutsugamushi reported. The 
clinical virulence is noted to be different with strain variation. Direct antigenic 
characterisation can be done using 2 methods. 
1. Black plate collection method: flat, square, black plastic tiles are placed on the 
ground; unengorged chiggers that attach to the plates are removed for rickettsial 
isolation. 
2. Chiggers infected are removed from the ears of the field trapped rodents and are 
processed for Orientia strains.  
There are various methods of serological characterisation which include complement 
fixation, toxin and serum neutralization, indirect fluorescent antibody assay and direct 
antibody fluorescent assay. The other recent techniques used which use other than 
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56kDa cell surface antigen genes are gel electrophoresis, restriction fragment-length 
polymorphism (RFLP), Polymerase chain reaction(1). 
Methods of Characterisation of Antigenic strain: 
Complement fixation (CF): CF is one of the earliest methods for clinical diagnosis 
of scrub typhus. It was used by shishido et al to confirm the identity of 3 original 
strains Karp, Gilliam and Kato strains. The principle of the test is that the amount of 
complement fixed is proportional to the mass of the antigen- antibody complex of the 
Orientia antigen. This test showed specificity with absence of cross-reaction with non 
scrub typhus group antigens. 
Cross-neutralization and cross-immunization: This method is very cumbersome. In 
cross neutralization assay serum from specific antibody is taken from hyperimmunised 
animals are incubated with Orientia organisms. The serum is injected into susceptible 
mice, infectivity is observed by the reducing ability of specific neutralizing antibody. 
It can also be compared by the monitoring cytopathic effect. 
The cross- vaccination or cross-immunization mice and guinea pigs are immunised 
with live or killed Orientia organism by a non lethal route such as subcutaneously. 
The strain variation can be characterised by looking at the Virulence of the inoculated 
animals. The strain variation can also be made out by using a toxin neutralization 
assay using with egg yolk sac viability. 
Immunofluorescence and immunoperoxidase assays: The initial sequencing of 
gene was done using direct fluorescent assay(DFA) and indirect fluorescent 
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assay(IFA).The strains used in the assays are anti-Karp, -Kato, -Gilliam, -TA678, -
TA686, -TA716, -TA763, and -TH1817 serum.  
Monoclonal antibody typing: Antibodies are specifically derived from reactive with 
the prototype strains. 
SDS- PAGE immunoblot assay: This technique uses electrophoresis from multiple 
strains of Rickettsia isolated from many different strains. The 56kDa protein is the 
most studied antigen for the electrophoresis, the other antigens used are 110kDa, 
70kDa, 60kDa, 56kDa, 47kDa, and 22-25kDa.The 56kDa antigen is located on the 
cell surface and is unique and has cross reactive epitopes, this is a specific protein 
which consists of 520 amino acids but can vary between 500-540 amino acids in 
different strains. The characteristic type specificity 16SrRNA was used to place scrub 
typhus in the new genus Orientia(1). 
The original prototype strains isolated were Karp and Gilliam (1943) and Kato (1955) 
in New Guinea, Assam-Burma border and Japan respectively. Many strains have been 
isolated from the endemic areas which include Shimokoshi, Kawasaki, and Kuroki 
from Japan and Boryong from Korea. The strain variation depends on 2 major proteins 
namely 110kDa and 56kDa major surface membrane protein. 
56kDa protein is a type specific antigen. Gene sequencing of this antigen has shown 
great genetic diversity between strains. The locus contains 4 hyper variable regions 
(VDI-VDIV). Altered base pairs in this region give rise to specific protein products 
which are strain specific and immunologically different. Phyllogenetic analyses have 
provided information regarding genetic diversity of various strains and their 
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geographical location. Gene coding for Karp strain was done by Stover in 
1952(13).According to the genotypic study system in Japan O tsutsugamushi was 
classified into Gilliam, JG(Japanese Gilliam), Karp, JP-1(Japanese Karp 1), JP-
2(Japanese Karp type 2), Kato, Kawasaki, Kuroki, Shimokoshi, and others. Kelly et al 
in their review of O. Tsutsugamushi strain distribution in the Asia – pacific region, 
have reported that each geographic focus has a predominant strain type. Overall karp, 
Karp-like  and Gilliam- like strains seems to be most prevalent(1).  
In India, Gilliam type strain was isolated by Bengston et al in Assam-Burma region in 
1943(14).The sera tested from outbreak in 1944 in Indo-Burma border showed that 
infection with multiple strains noted were Gilliam(36%), followed by Karp(7%) and 
Seerangayee (7%). In 2004 a study from Himachal Pradesh showed the strains 
identified on PCR were Karp and JP1 and Satitama and JG type(15).In a recent study 
done in 2007 where 66 samples were tested by RT PCR( real time PCR) showed the 
strain to be close to Kuroki type(16).In a study done in our institution in 2013 on 26 
samples showed 17(65%) to be of Kato type and 8(31%) to be of  karp like group(2).  
Nayakayama et al have completed the sequencing of two strains namely Boryong and 
Ikeda; it has a single circular chromosome made up of 2 million base pairs with G+C 
pairs forming almost 30% of the base pairs. The genome had about 4197 identical 
base pairs. Major proportion of the high copy number tandem repeats coded for 
mobile genetic elements including conjugative transfer genes, transposons and phage 
genes .Of these 359 tra genes coding for Type IV secreting system (TFSS), which is a 
conjugative system for transfer of DNA from one cell to another, were identified,  
Presence of such a system in an intracellular bacteria, like O. tsutsugamushi, is 
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unusual and may facilitate both vertical inheritance(in primary host) and horizontal 
transfer in secondary ones (man, rodents)(17)(18). 
Table 1:Epidemiological prevalence studies showing geographic distribution of 
predominant strains, Adapted from Kelly et al(1). 
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Vector and its life cycle: 
The etiological agent of scrub typhus is Rickettsia, the reservoir for which is mainly 
the rat, field mouse, or the bandicoot. The organism is transmitted to man by the bite 
of larval form of the mite Trombiculia akamushi, T. deliensis, and T. hirsti. The larval 
mite is seen in grass, brush, and secondary jungle growth consisting of stunted trees 
namely scrubs. The mite acquires the organism by sucking on the infected vertebrate 
host(19). There are several species of Leptotrombidium, each with its characteristic 
geographic distribution. L. deliense appears to be the primary vector in most countries 
including India. There was a new species of vector for scrub typhus was noted in 
Darjeeling namely Schoengastiella lingual as the vector of scrub typhus. 
 
Table 2: Putative vectors of human scrub typhus and their geographic foci(1). 
 
 
 30 | P a g e  
 
LIFE CYCLE 
Humans acquire the disease by the bite of an infected mite. The adult mite has four 
staged lifecycle namely: 
1. Egg 
2. Larva 
3. Nymph 
4. Adult. 
The egg deposited by the adult female develops into larval form called chiggers. They 
aggregate to form the mite islands /typhus islands which are mainly seen in the shrubs 
and the grasslands awaiting hosts such as rodents and small animals. These larval 
forms feed on the meal of the blood of the vertebrate host thereby acquiring the 
disease and transmitting the pathogen. Once engorged with blood the chigger falls off 
from the body and continues to form nymphal and then adult forms. The larval stage 
of the organism feeds only once in the life time (figure on the life cycle). 
The larva also called as the chigger is the only stage that can transmit the disease to 
humans and other vertebrates, as the other stages do not feed on vertebrate animals. 
Chigger mites act as the primary reservoir for the organism. They are infected by 
feeding on the bodily fluid of the infected vertebral host. The infection is passed on to 
all the stages of the lifecycle by transovarial transmission, where the infection is 
passed on to from adults to other stages through the egg. The infection is also passed 
on from the egg to the larva is called transtadial transmission. Earlier studies thought 
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rodents as the natural reservoir, however recent studies have revealed that the mites 
act as the vector and also the reservoir(20). 
Humans act as the dead end host with no human to human transmission. The disease 
is seen more commonly as there is encroachment of the scrub land by the agricultural 
and wartime activities making soldiers and farmers more susceptible for the acquiring 
of the disease(1). 
Figure 3: Life cycle of Scrub Typhus 
 
PATHOGENESIS:  
O. tsutsugamushi survives in the wild in a cycle involving trombiculid mites and other 
vertebrates. Humans act as the accidental hosts for the organism. O tsutsugamushi is 
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different from rickettsia in the genetic makeup, cell wall structure. The organism acts 
as an obligate intracellular gram negative bacterium. The larval stage of the mites 
(chiggers) harbouring the bacterium after biting the exposed individuals multiplies at 
the site of inoculation causes local and systemic manifestations. 
O. tsutsugamushi inoculated in the saliva of the chigger after the bite to the skin 
mainly enters the dendritic cells and macrophages in the dermis of the underlying 
eschar at the site of inoculation. Attachment and entry of the obligatory intracellular 
organism is by the clatrin-dependent endosomal pathway which involves the 56kDA 
surface protein, host fibronectin autosomal transporter(ScaC), integrin-a5b1 and 
syndecan-4 host cell receptors(21). 
Immune response  
The organism induces both humoral and cell mediated immunity. The immune 
response is complicated in view of great antigenic diversity. Homologous immunity is 
provided by the major surface antigen, 56 KDa protein molecules that contain strain 
specific epitope. The antibodies to 56kDa molecule increase uptake by the 
macrophages and neutrophils and cause clearance of the organism. The protective 
immunity is mediated by the TH1 response. The various cytokines which rise during 
the acute infection are macrophage colony stimulating factor (M-CSF), interferon 
gamma (IFN-V), and granulocyte colony stimulating factor (G-CSF), interleukin 
1beta, IL-12p40, tumour necrosis factor alpha, IL-10, chemokines such as CXCL-9 
and CXCL-10. Few patients also showed a rise in tumour necrosis factor (TNF –
alpha), this tumour marker is also seen to increase in the convalescence period. 
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However the role of CD4 cells and CD8 cells, natural killer cells, NKT cells, dendritic 
cells. Macrophages and endothelial cells have not been evaluated in disease 
models(21). 
There is also indirect evidence for cytotoxic lymphocyte activation, cytotoxic T cell 
and natural killer cell activation during acute infection. This plays a role in destroying 
the infected host cells. 
The organism has developed mechanisms to evade the immune mechanisms. Cho et al 
showed that the organism down regulates the expression of the glycoprotein 96(gp 96) 
in the macrophages and endothelial cells. This molecule is expressed in the 
endoplasmic reticulum of the cells and plays a central role in the major 
histocompatibility complex class I antigen presentation; the suppression of this 
glycoprotein plays a major role in the neutralization of the host response(22). 
It has three phases, first at the site of inoculation, second, systemic dissemination, 
endothelial dysfunction, and vasculitis lastly, antibody mediated phenomenon. 
Disseminated vasculitis is central to the pathogenesis of scrub typhus. 
Inoculation- Eschar 
The eschar is the initial site of inoculation, is a result inflammatory response to the 
bite of the chigger. The eschar produces in rapid order a papule, vesico-papule, 
excoriated papule, frank eschar, ulcer and finally a small scar. The lesion evolves over 
3-4 weeks and can get prolonged in case of secondary infection such as in groin or 
axilla. The maximum diameter of the eschar is around 5mm and the surrounding 
erythematous area is also of the same diameter(19). The initial inflammation can 
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spread to the mid dermis with polymorphonuclear cells in the upper zones with 
increasing monocytes in the deeper zones. There is an acute thrombophlebitis and 
arteritis within the zone of inflammation surrounded by area of mononuclear 
infiltration within the venules. 
Systemic dissemination 
The endothelium forms the principle site of inoculation of the organism. Between 
1916 and 1922 the giemsa stain demonstrated the rickettsia to be in the endothelial 
cells of the cutaneous biopsies and autopsies by Wolbach et al. Allen and spitz et al 
showed that the organism was noted in the eschar and also on some cases in the 
macrophages and spleen. The organisms are found in the endothelial cells of the 
myocardial capillaries and in cardiac myocytes. The cytoplasm of the capillary 
endothelial cells was consistently found to have the organisms. The rickettsia is 
known to exit from the host cell by budding from the plasma membrane(23). There is 
also evidence to show that the organism was seen within the mononuclear cells of the 
acute phase of the scrub typhus illness. There are also reports to show that the 
organism is seen in the dendritic cell/macrophages. The organism after inoculation 
into the skin spreads to the regional lymph node which is followed by systemic 
dissemination. The organism thus may use the haematogenous and also indirectly by 
the lymphatic system for systemic dissemination(24)(25). 
Thus the organism mediates intracellular events leading to the generation of the 
reactive radical in the host cells, cytokines and increases cytotoxic immune cells 
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leading to the pathophysiological effects such as increased vascular permeability 
leading to edema, vasculitis(21). 
The severity of the illness depends on both host and pathogen related factors. The 
bacterium multiplies in the principal target sites which is the endothelial cells. It 
affects the endothelial cells of the heart, lung, brain, liver, kidney, pancreas, skin. It 
also affects the macrophages of liver and spleen. The organism gains entry into the 
body through the lymphatic cells. It has also been demonstrated that there is a 
possibility of blood borne infection as the organism was found in the mononuclear 
cells(22). 
Persistence of infection 
The persistence of the organism was described in infected mice, where the organism 
was found in the body for up to 610 days after inoculation(26)(27). Smadel et al 
showed that the organism can be isolated from lymph node after 2 years after the 
infection of an asymptomatic person(28). Chung et al showed that the blood of six 
individuals who had scrub typhus, the organism was isolated after 1-18 months after 
the infection(29). The persistence of the organism needs further evaluation. 
The vaccine development has failed multiple attempts for the past 70 years. The 
various approaches used were formalin-killed Orientia, inoculation of viable 
organisms followed by antimicrobial treatment, irradiated O. Tsutsugamushi and 
subunit vaccines(28)(30)(31). The results varied from short term to failure to protect. 
There has been failure to stimulate cross- protection against many strains in the nature 
after natural infection(32).   
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CLINICAL FEATURES 
Scrub typhus is also known as the tsutsugamushi disease. It presents as an acute 
febrile disease. The illness varies from a mild and self limiting illness to a fatal 
disease. The case fatality rate of patients requiring admission in the hospitals was 
4%(33).The incubation period varies from 6-21 days. The onset is characterised by 
fever, headache, myalgia, cough and gastrointestinal symptoms. 
Classical course: 
The classical description of the illness includes a primary papular lesion, which is the 
site of bite of the chigger. This site enlarges and undergoes central necrosis and crusts 
to form an eschar. The eschar is usually flattened and black in colour. About half of 
the patients develop non pruritic, macular or maculopapular rash, some patients also 
develop petechiae. The rash begins in the abdomen and spreads to the extremities. 
This is followed by regional lymphadenopathy and later generalised 
lymphadenopathy. The symptoms gradually increase in the severity with associated 
macular rash on the trunk. This leads to multiorgan involvement namely the central 
nervous system, respiratory, cardiovascular and gastrointestinal systems. Patients 
remain febrile for about 2 weeks and have a long convalescence of 4 to 6 weeks if left 
untreated(34). 
Eschar: 
Some patients develop a localised necrotic skin lesion at the site of the chigger bite. 
The eschar represents the site of inoculation where initial multiplication occurs before 
widespread dissemination. The eschar is usually painless and non-pruritic and usually 
 37 | P a g e  
 
not reported by patients(35). The eschar may develop before the systemic symptoms 
and can occur in multiple locations. The frequency of the eschar can be variable. A 
study from Vietnam in 1973 showed a prevalence of 46%(36), sheehy et al showed an 
incidence of 60 to 88%(6). A study done in our institution in 2013, in 418 patients 
showed a distribution on the chest and abdomen (42.3%) in females, and in groin and 
genitalia (55.8%) in males. The unusual sites of the eschar are in the cheek, ear lobe 
and the feet(37). 
Generalised lymphadenopathy is usually seen in majority of patients and usually 
accompanied by inflammation of lymphatic sinuses, splenomegaly and portal triaditis.  
Relative bradycardia occurs commonly in scrub typhus, which is defined as a median 
decrease in heart rate <10beats/min per 1ºC increase in the temperature. 
Complications of scrub typhus: 
Scrub typhus involves multiple organs due to the microangiopathies leading to focal 
vasculitis or perivasculitis.  
Respiratory system involvement 
Pulmonary involvement is a well documented complication of the scrub typhus. The 
basic pathologic process in pulmonary involvement of scrub typhus is interstitial 
pneumonia with or without vasculitis(38).Pleural effusion is the most common 
radiographic feature with a prevalence of 12-55% in various studies(34). Cough 
occurred in up to 45% of the patients as shown by Berman et al(36). The other 
pulmonary manifestations are bronchitis, interstitial pneumonitis progresses to acute 
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respiratory distress syndrome, pneumonitis with patchy consolidation, pulmonary 
edema, cardiomegaly, hilar adenopathy, focal atelectasis, reticulonodular opacities, 
bronchial wall thickening and centrilobular nodules. Acute respiratory distress 
syndrome (ARDS) is defined as an acute and persistent lung inflammation with 
increased permeability has been reported in severe scrub typhus. The incidence of 
chest x-ray findings with scrub typhus varies between 59.4-78%(34). In a study done 
in Thailand 2006, 65% of patients had radiographic abnormalities(n=130), the most 
common abnormalities were bilateral reticular opacities(49%), congestive heart 
failure(19%)(39). 
Cardiac disease: 
Myocardial lesions were observed in about 80% in an autopsy series(40). Vasculitis 
and perivasculitis in the myocardium induce cellular infiltration along with 
haemorrhage and edema of interstitial tissues. Myocarditis is known to be associated 
with scrub typhus though incidence is not ascertained. IN critically ill patients scrub 
typhus patients cardiovascular abnormalities were seen in 61.7%(41).Cardiomegaly 
may be due to myocardial and pericardial involvement(38).  
Renal involvement: 
Renal abnormality has been reported in up to 82% of patients with scrub typhus. 
Acute kidney injury was reported in the 18-30% of cases, and in those requiring 
intensive care in up to 63.8%. Albuminuria and microscopic hematuria in 55-59% and 
16-44%(41)(42).  
Gastrointestinal and hepatic involvement: 
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Nausea, vomiting and diarrhoea are noted in one fourth of patients. Kim et al in 2000 
showed 58% of patients with prominent gastrointestinal symptoms from 256 patients 
had superficial ulcers, erosions and actively bleeding ulcers(43). Abdominal pain is 
seen in 21.7% of those presenting with scrub typhus. Vomiting is seen in nearly 50% 
of patents and diarrhoea in 10-20% of cases. Acalculous cholecyctitis and pancreatitis 
progressing to pancreatic abscess has also been reported. Liver involvement is seen in 
over 60% of cases with scrub typhus. The common abnormalities noted are 
hypoalbuminemia, elevation of liver enzymes and alkaline phophatase and direct 
hyperbilirubinemia have been seen. Jaundice is seen in 132-22.2% of patients with 
scrub typhus. In a study done in our institution by chrispal et al showed a mean value 
of 2.1mg/dl (+ 2.4mg/dl).  Severe hepatitis was not very common. The mean 
SGOT/SGPT values were 163.7 (±138.3) and 104.8 (±70.7) (U/L) respectively and 
serum ALP being 177.9(+127 U/L). Hypoalbuminemia has been seen in 68% of 
patient with scrub typhus in a study done by Razak et al. Add references.   
Central nervous system (CNS) disease: 
Scrub typhus is derived from the term “typho” meaning “stupor”. The CNS is affected 
in 20-30% of patients infected by rickettsia. The CNS involvement in variable, the 
most common involvement is meningoencephalitis, other involvement includes 
encephalomyelitis. The various manifestations central nervous system are 
 
1. Altered sensorium 
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Altered sensorium is seen as a part of encephalopathy in Scrub Typhus. A study done 
in Christian Medical College, Vellore by chrispal et al showed that the prevalence of 
altered sensorium was 22.2-32% in patients with scrub typhus(44). A study from 
Korea, the altered sensorium was seen in 2.6% of patients(45). Chrispal et al found 
altered sensorium to be an independent predictor of mortality(46).  
2 Meningitis and encephalitis syndrome 
Meningitis is a common CNS manifestation associated with Scrub Typhus. The 
symptoms noticed are nuchal rigidity and CSF analysis shows more than 5 cells/mm. 
Encephalitis is characterised clinically seizures and altered sensorium. There are few 
case reports of focal signs. The clinical syndrome may be mistaken for bacterial, viral 
or tubercular meningitis.  
In a study from CMC, chrispal et al showed the prevalence of meningitis was 20.6%. 
Meningitis and meningoencephalitis presented with largely headache, neck stiffness, 
altered sensorium and seizures with CSF analysis suggestive of aseptic 
meningitis(46).  In India the incidence of meningitis and meningoencephalitis ranged 
from 14 to 26%. Mahajan et al in 2006 reported a incidence of 21%(47), where as a 
study done in Karnataka showed an incidence of 20%(48). Vivekanandan et al 
reported aseptic meningitis in 14% of the 50 patients(49). In our institution a 
prospective study by chrispal et al showed the incidence to be 20.6%, while a 
retrospective study done by Varghese et al, in 623 patients showed incidence of 
23.3%. Vishwanathan et al showed the incidence of 26% in patients with scrub typhus 
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meningitis. In a study done Kar et al 30% of cases presenting with acute encephalitis 
had scrub typhus.  
3 Cranial nerve involvement: It is noted in scrub typhus to have cranial nerve 
involvement. The most well known cranial nerve involvement includes vestibulo 
cochlear nerve(1). The other nerves noted are optic, facial and abducens 
nerve(50)(51). 
4 Cerebellar involvement:  
Acute and subacute cerebellar involvement is noted in isolation or in combination 
with meningitis with scrub typhus. Cerebellar involvement is characterised by 
truncal ataxia, horizontal nystagmus with aseptic meningitis. In a series form 1991, 
scrub meningitis was associated with bilateral cerebellar signs in 72 of the 
patients(52). One case of cerebellitis was also noted in a series with scrub typhus 
by Razak et al(48). 
5 Other central nervous system involvement: 
Involvement of spinal cord is not very common with scrub typhus. There was a case 
by Kim et al of involvement of brain stem with associated bilateral facial and 
abducent palsy, with associated dysarthria and dysphagia in the 3
rd
 week of the illness. 
Imaging (MRI) showed a non specific T2 hyperintense and T1 hyperintense lesions. It 
was also noted to have a gradual resolution with therapy(53).  Acute disseminated 
encephalomyelitis (ADEM) is also reported in patients with scrub typhus with a rapid 
course and variable resolution with therapy. Transverse myelitis is also reported in 
patients with scrub typhus(54). 
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Peripheral nervous system involvement in the form of neuritis is noted with an 
incidence of 5.5%(55).Motor, sensory and mixed neuropathy are noted in patients 
with shoulder girdle most commonly involved. There are case reports of isolated 
brachial plexopathy after resolution of scrub typhus(56). Gullaine barre syndrome an 
ascending areflexic polyradiculopathy is noted with scrub typhus in few case 
reports(57).  In India sawale et al noted a case of ascending flaccid quadriparesis and 
facial palsy in the convalescent period of the scrub typhus infection(58). 
Extrapyramidal syndromes are also seen in scrub typhus. Acute parkinsonism was 
noted in 1946 by ripley et al(55). Movement abnormalities like tremors was noted in 
patients with scrub typhus meningitis by pai et al(59). Opsoclonus- myoclonus of a 
special clinical syndrome associated with scrub typhus, where there spontaneous 
ocular motility characterised by spontaneous, saccadic, arrhythmic and conjugate 
saccade without saccadic interval. Myoclonus is characterised by brief, shock like, 
involuntary movements caused by muscular contractions and inhibitions.  
 
DIAGNOSIS 
As in all the rickettsial infections no laboratory test is diagnostically reliable in the 
early phases of scrub typhus. The disease is recognised with compatible clinical 
symptoms, signs and laboratory features. Epidemiological factors aids in the diagnosis 
such as recent exposure to chiggers. 
Laboratory parameters: 
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The common laboratory abnormalities noted in patients are thrombocytopenia which 
is associated with severe illness. Liver dysfunction in the form of elevation in the 
hepatic enzymes, bilirubin are seen. Renal failure leading to elevated creatinine is 
seen. They can have both leukocytosis, leucopoenia or in some instances the total 
leukocyte count can be in the normal range.  
Definitive diagnosis 
The diagnosis of scrub typhus can be definitively confirmed by four methods 
1. Serology : 
a) Indirect fluorescent antibody test (IFA) remains the mainstay of serologic 
diagnosis and is the gold standard for the diagnosis of scrub typhus.  The diagnosis is 
confirmed by a fourfold increase in the titer from the samples drawn 14 days apart. 
The most commonly used strains for the test are the Kato, karp and Gilliam strains, 
and it uses fluorescent anti human antibody against the strains. It has been seen to 
have a large antigenic variability. The most common cut-off titer used is 1:50(5). It is 
more sensitive than the weil felix test(60).  
b) ELISA (enzyme linked immunosorbant assay): ELISA has been developed 
which helps in rapid analysis of the sample. The 56kDA protein of the organism 
which is located on the rickettsial surface was cloned and was expressed as a fusion 
protein with maltose-binding protein of Escherichia coli by deleting the 252 base pairs 
from the 5’end. The recombinant protein was used for detection of the antibody in 
human sera. This yielded a sensitivity of 95% and specificity of 100%(61). 
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c) Weil Felix test: This was the oldest test which was in use, which was relatively 
inexpensive and easy to perform. However it lacks sensitivity and specificity. 
 
2. Biopsy of eschar: 
Eschar forms the pathological hallmark of scrub typhus. Damage to the endothelial 
cells occurs early in the infection and is evidenced by lymphohistiocytic vasculitis. 
Thus demonstration of the histological features of cutaneous necrosis, intense 
vasculitis with perivascular collections of lymphocytes and macrophages forms the 
hallmark of the disease. These can be demonstrated by fluorescent antibody 
conjugates even in the absence of rickettsia.  
3. Culture: 
Culture of this organism requires bio safety level-3 facilities and has to be cultured on 
a cell monolayer with median time to positivity being 27 days. Hence current methods 
of isolation of the organism are not appropriate for routine diagnosis of scrub 
typhus(60).  
4. Polymerase chain reaction (PCR): 
PCR can definitively establish the diagnosis of scrub typhus even in patients who lack 
IgM antibodies in the early course of the infection. The sensitivity of PCR was 85% 
and specificity was 100% in a study from Korea. In addition to serum PCR, eschar 
PCR is also sensitive and specific for the diagnosis(62). The PCR testing for 56kDA 
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antigen protein has been found to be highly specific. However the assay involving 
16SrRNA showed a sensitivity of only 37.5-52.3%(60). 
5. Loop isothermal amplification (LAMP): 
It is a technique which is used to amplify the DNA using three specifically designed 
primer pairs and the Bst DNA polymerase. The entire reaction takes place at the same 
temperature. The reaction is read visually not requiring any special equipment. It is 
noted to detect as low as 14 copies/micltr compared to 3 copies/mic ltr in PCR(60). 
The other tests which have been used are indirect immunoperoxidase (IIP), integrated 
diagnostic dip-stick test. 
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Table 3: Tests used for Scrub Typhus 
 Adapted from Gavin C.K.W.Koh et al 2010(60). 
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MANAGEMENT 
Scrub typhus is caused by a mite-borne infectious disease caused by Orientia 
tsutsugamushi. It is manifested by high fever, intense generalised headache, diffuse 
myalgia, associated with rash and eschar at the chigger bite. Scrub typhus lasts for 14 
to 21 days without treatment. It may be associated with multiorgan system 
involvement, death may occur due to these complications. The patients treated with 
appropriate antibiotics become afebrile within 48 hours of starting therapy. Failure of 
defervescence within 48 hours is considered evidence for alternate diagnosis other 
than scrub typhus(6).   
 
Antimicrobial therapy 
There are various groups of antibiotics which have been tried in the therapy for scrub 
typhus.  
1. Chloramphenicol: 
Chloramphenicol is a bacteriostatic drug which acts by inhibiting protein synthesis. It 
acts by preventing the protein chain elongation by inhibiting the peptidyl transferase 
activity of the ribosome(63). It is known to specifically bind to the A2451 and 
A2452(64) residues of the 23S rRNA of the 50S ribosomal subunit thus preventing the 
peptide bond formation. It is very small molecule which is extremely lipid soluble and 
remains unbound to the protein. It penetrates effectively into all the tissues of the body 
including the brain. 
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Figure 4: Chloramphenicol molecule 
 
 
2. Doxycycline and tetracycline: 
It is a broad spectrum antibiotic of the tetracycline class. It is useful against bacterial, 
protozoal and helmithic organisms and rickettsial infections(65). Doxycycline- metal 
ions are stable in the acidic pH, hence it is absorbed in the duodenum (66). The drug 
acts by entering the bacterial cell and reversibly binding to the 30s ribosomal subunit 
at the position blocking the binding site of the aminoacyl-tRNA acceptor site. This 
leads to inhibition of the protein synthesis(67).   
Figure 5: Doxycycline molecule 
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3. Azithromycin: 
Azithromycin belongs to the azalide class which is a subclass of macrolides antibiotic 
class. It is derived from erythromycin with a methyl substituted nitrogen atom into the 
lactone ring. This makes Azithromycin a 15 member ring. It has a broad but shallow 
spectrum of antibacterial activity. It inhibits gram positive, gram negative and also 
atypical bacteria(68). It acts by interfering the protein synthesis by binding to the 50S 
ribosome unit and inhibiting the translation of mRNA. It is an acid stable antibiotic, 
hence facilitating oral intake of the drug. The drug gets concentrated in the phagocytes 
hence it gets actively transported to the sites of the infection. It has a long half life 
hence allowing a single dose therapy. However the nucleic acid synthesis is not 
affected by the drug(69). It has been used successfully in treatment of scrub typhus 
and other Rickettsial infections.  
Figure 6: Azithromycin- molecule 
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4. Roxithromycin: 
It is a semi-synthetic macrolides antibiotic which is also derived from the 
erythromycin antibiotic. It comprises of a membered lactone ring. It binds to the 50S 
ribosome and thus inhibiting the translocation of the peptides. It has similar 
antimicrobial spectrum as compared to erythromycin(70). There are various trials 
using roxithromycin for treatment of rickettsial infections. 
Figure 7: Roxithromycin molecule 
 
5. Rifampicin: 
It is a bactericidal antibiotic of the rifamycin group. It acts by inhibiting the bacterial 
DNA- dependent RNA synthesis by inhibiting the DNA- dependent RNA 
polymerase(71)(72). It can be used in variety of infection; it has been tried in patients 
with infection with rickettsial infections. 
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Figure 8: Rifampicin molecule: 
 
 
Evidence for antibiotic usage in scrub typhus 
Chloramphenicol was the first drug to be shown effective against scrub typhus and is 
commonly in endemic regions. Sheehy et al in 1973 included 63 participants, in which 
30 received Chloramphenicol and the rest tetracycline with the outcome looked at was 
duration of fever and afebrile after 48 hours. It was found that the mean duration of 
fever in tetracycline arm was 28 hours and in Chloramphenicol arm was 35 hours, 
relapse was noted in 2 participants in the tetracycline arm and 5 in the 
Chloramphenicol arm(6)(73).  
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Figure 9: Adapted from Sheehy et al(6). Forest plot of comparison of fever, 
tetracycline v/s Chloramphenicol 
 
There are five trials comparing Azithromycin and Chloramphenicol. There were 4 
studies which compared duration of fever, symptom clearance and all the 5 studies 
compared treatment failure between the two groups. Li yuan et al 2004 included 136 
subjects and the outcomes considered were adverse effects, fever clearance time, cure 
and disappearance of main symptoms(74). Wei et al included 62 subjects and they 
looked at cure and adverse effects(75). Wu xiang et al in 2006 looked at cure and 
disappearance of main symptoms including 62 subjects(76). Li et al in 2007 looked at 
fever clearance time, cure, disappearances of main symptom and adverse drug effect, 
studying 20 subjects(77). Chen et al studied 279 subjects to study fever clearance 
time, cure and adverse effects(78). Metaanalysis done showed Q test being significant 
for heterogeneity for duration of fever and symptom among the above said trials. The 
mean duration of fever clearance time was higher in Azithromycin arm than in the 
Chloramphenicol arm with a mean difference of 12.66 hours. However there was no 
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difference in the two arms in perspective to symptom clearance time and treatment 
failure(79).  
 
Figure 10: Adapted from Fang y et al(79).Forest plot for duration of fever between 
Azithromycin and Chloramphenicol. 
 
 
Figure 11: Adapted from Fang y et al(79). Forest plot for adverse effects between 
Azithromycin and Chloramphenicol 
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There are six trials compared doxycycline and Chloramphenicol. Li yuan et al 2004 
included 136 subjects and the outcomes considered were adverse effects, fever 
clearance time, cure and disappearance of main symptoms(74). Yang et al in 2005, 
compared cure and disappearances of main symptoms(80). Wu xiang et al in 2006 
looked at cure and disappearance of main symptoms including 62 subjects(76). Li et al 
in 2007 looked at fever clearance time, cure, disappearances of main symptom and 
adverse drug effect, studying 20 subjects(77).Feng et al included 210 subjects, 
compared cure and disappearance of symptoms(81). Phimda et al looked at 57 
subjects and studied cure failure, defervescence and adverse events(82). Main 
symptom clearance time in days was shorter in doxycycline treated group compared to 
Chloramphenicol group with a mean difference of -0.4 days(79). 
 
Figure 12: Adapted from Fang y et al(79).Forest plot for main symptom clearance 
between Doxycycline and Chloramphenicol. 
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Figure 13: Adapted from Fang y et al(79).Forest plot for adverse events between 
Doxycycline and Chloramphenicol. 
 
Azithromycin and doxycycline was studied in three randomised trials. Phimda et al 
looked at 57 subjects and studied cure failure, defervescence and adverse events(82). 
Li et al in 2007 looked at fever clearance time, cure, disappearances of main symptom 
and adverse drug effect, studying 20 subjects(77). Kim et al included 93 and looked at 
time to fever defervescence, cure, failure, adverse effects(7). There was no difference 
detected in duration of fever, symptom clearance time and treatment failure. However 
the adverse events were less likely to occur in Azithromycin treated group(79).  
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Figure 14: Adapted from Fang y et al(79).Forest plot for adverse events between 
Doxycycline and Azithromycin. 
 
Three trials compared roxithromycin and doxycycline which showed no difference in 
terms of treatment failure and symptom clearance time. Two trials compared 
rifampicin and doxycycline which had no difference for the event, or adverse events. 
There was no difference between tetracycline and doxycycline(79).  
Treatment with doxycycline showed rapid reduction of clinical manifestations, oral 
doxycycline is the currently the standard of treatment for mild cases(82).  
Azithromycin is reported to be equally effective as doxycycline for the treatment of 
scrub typhus, with lesser gastrointestinal symptoms(73)(7).   
A study done in three centres in Thailand by K Phimda et al in 2014,included 296 
patients of which 69(23.3%) had leptospirosis, 57(19.3%) with scrub typhus and 
14(4.7%) with murine typhus and 11 (3.7%) with co-infection with leptospirosis and 
rickettsial infection. The study compared Azithromycin and doxycycline, the results 
showed that the overall cure rate of Azithromycin (97.4%) was non-inferior to 
doxycycline (96.5%) treated arm. Among patients with laboratory confirmed scrub 
typhus, treatment failure occurred in 1 patient, the median time of fever defervescence 
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was 48 hour in doxycycline group and 60hour in Azithromycin group. However 
doxycycline showed earlier defervescence than Azithromycin group(83). 
 
FEVER DEFERVESCENCE 
 
 
It has been seen that there is a delayed defervescence in fever in patients with 
appropriate therapy for scrub typhus. Chung et al, 2008 studied 130 cases, which had 
38 patients with scrub typhus, 61 with Q fever and 7 with murine typhus. All the 
patients received 200mg orally in two divided doses per day of doxycycline. 7 patients 
with scrub typhus had delayed defervescence. Relative bradycardia, jaundice and 
absence of headache were associated with delayed defervescence. The postulate for 
delayed defervescence is the probable presence of resistant strains to doxycycline(8). 
All the studies thus far have compared antibiotics and have shown to have similar 
results with therapy. There is lack of studies looking at antibiotic profile in patients 
with severe scrub typhus disease and the resolution of the organ failure. Role of 
combination therapy in scrub typhus hasn’t been studied in terms of non inferiority or 
superiority to monotherapy. The proposed study aimed at studying the shortcomings 
of the earlier studies. 
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MATERIALS AND METHODS 
 
Study Setting: 
The study was conducted in Christian Medical College, Vellore. This is a 2700 
bedded academic medical centre providing tertiary medical care to the residents of 
Vellore and surrounding districts of Tamil Nadu and Andhra Pradesh. It is also a 
referral care centre for patients from other parts of India and South East Asia. 
 
 Duration: The study was conducted between November 2013 and January 2015. As 
Scrub Typhus is a seasonal disease which is more prevalent in the cooler months of 
the year, two seasons were included in the study. 
 
Study Design: 
This was a prospective observational cohort study. 
Participants:      
The study included all patients older than 18 year of age with acute undifferentiated 
febrile illness with a diagnosis of Scrub Typhus presenting to the hospital to 
Outpatient department, Intensive care unit /High dependency unit/Medical wards.  
We recruited a total of 223 patients from November 2013 to January 2015. 
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Inclusion Criteria: 
All adult patients aged > 18 years of age presenting with an acute undifferentiated 
febrile illness, with clinical profile suggestive of scrub typhus with. 
1. Positive Scrub Typhus IgM Elisa and/or 
2. Presence of a characteristic eschar. 
Exclusion criteria: 
1. Patients with acute febrile illness with a definitive etiological diagnosis other than 
scrub typhus. 
2. Patients on immunosuppressive agents or known to be immunocompromised. 
3. Patients with a known autoimmune disorder. 
4. Patients with a known malignancy on chemotherapy. 
 
Rationale for Diagnosis and Inclusion: 
An eschar correlated with a serological positivity of 99% of cases suspected to have 
scrub typhus. In addition our experience has shown good clinical response to therapy 
for scrub typhus in those presenting with appropriate clinical symptoms and an eschar. 
Hence in our setting, an eschar was considered diagnostic of scrub typhus. 
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Serological testing was done using Scrub Typhus Detect IgM ELISA (InBios). 
Positivity was indicated with titers more than or equal to 0.5 OD. This kit uses a 56-
kDa recombinant cocktail of antigens (Karp, Gilliam, Kato and TA763). It has 86.5% 
sensitivity and 97.5% specificity. 
Patients with active of past history of autoimmune disease, immunosuppression and 
malignancies on chemotherapy which could have a probable confounding effect on 
the defervescence pattern were excluded from the study. 
Methodology: 
A single centre observational prospective cohort study was done to determine the 
factors associated with outcome of scrub typhus between November 2014 to february 
2015.A written informed consent was taken from either the patient, or from the legal 
guardian in those with altered mental status, prior to the enrollment. All patients 
fulfilling the inclusion criteria were recruited within 24 hours of the presentation to 
the hospital. All patients with a positive scrub typhus IgM and or a characteristic 
eschar were included for the study and further analysis. 
A study form/data abstraction sheet which included patient’s demographic details, co-
morbidities, and clinical features was noted (attached as annexure). The details of 
antibiotics used by the treating physician including the time of administration, 
duration and the types of antibiotics used were recorded and the choice was not 
influenced by the study. In this centre three regimens are in practice namely 
doxycycline group, azithromycin group and the combined group receiving 
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doxycycline and azithromycin. Azithromycin is preferred in children and pregnant 
women, however the combination is more commonly used in the severely ill subjects 
as oral doxycycline absorption is suspected to be erratic in this group. 
Severity of the acute illness was assessed by using sequential organ failure assessment 
(SOFA) score was used which was repeated three times in patients getting admitted to 
critical care units. These were assessed within 48 hours after the admission and 
sequentially after 48 hours. The SOFA score is a standardized score used to assess the 
severity of the illness; it includes the P/F (PaO2/FiO2) Ratio, the GCS (Glasgow coma 
scale), total bilirubin, platelets, creatinine with increasing score indicating increasing 
severity of the illness. It has a direct correlation with the mortality as the outcome.   
 
The outcomes assessed were 
Primary: 
The incidence of delayed defervescence in patients treated with azithromycin, 
doxycycline and the combination of the two. 
 
Secondary: 
a. Factors associated with delayed defervescence. 
b. Duration of organ recovery. 
c. Comparison between the antibiotic regimens with respect to time of defervescence 
across the 3 arms. 
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Definitions 
The time of defervescence will be defined as the first day of the highest body 
temperature lower than 37.7°C (100°F) for more than 3 consecutive days without the 
use of antipyretics.      
Multi-organ dysfunction: Involvement of any 2 of the following organs was 
considered as having dysfunction (4). 
a. Respiratory dysfunction: SAO2<90% or PaO2/FiO2 ratio< 300 or need for 
ventilator assistance;  
b. Renal dysfunction: Serum Creatinine > 2mg/dl or need for dialysis;  
c. Cardiovascular dysfunction: Hypotension(<80/60mmhg) or need for inotropes or 
vasopressor support;  
d. Hepatic dysfunction: Serum Bilirubin >2mg/dl or three fold elevation of liver 
enzymes;  
e. Neurologic dysfunction: Alteration in the level of consciousness. 
 
Exposure: All with diagnosed scrub typhus infection (as per case definition) 
Potential confounders: 
a. Use of antipyretics and analgesics 
b. Spontaneous resolution of fever without antibiotic treatment 
c. Steroid use. 
Follow up: The patients were followed up for a period of 2 weeks after recruitment. If 
discharged earlier than 2 weeks a telephonic call was made to determine the outcomes. 
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STROBE STATEMENT- STUDY FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographic, clinical, laboratory features   
Antibiotic regimen will be noted 
1. Doxycycline group 
2. Azithromycin group 
3. Doxy+Azithromycin group 
Doxycycline Doxy+Azithromycin 
 
Azithromycin   
Fever defervescence  
Time 
Fever defervescence  
Time 
 
Fever defervescence  
Time 
 
                                   Analysis  
Defervescence time will be noted as 
primary outcome 
   Patients diagnosed to have Scrub Typhus 
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1. Sample size   
The sample size was calculated based on the primary outcome which is finding the 
incidence of delayed defervescence in all scrub typhus patients who have been 
treated with Azithromycin, doxycycline and the combination of the two. The sample 
is sufficiently large to compare the three arms. 
              Single Proportion - Absolute Precision 
Expected proportion 0.21 
Precision (%) 5 
Desired confidence level  (1- alpha) % 95 
Required sample size 255 
 
       
                
            
Scrub typhus patients with multiorgan failure 
Clinical organ resolution profile till discharge 
or death 
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The sample size to show an incidence of 21.5% of delayed defervescence with a 
Precision of 5% was found to be 255 subjects with 95% confidence limits. 
   
         Formula: 
        
         n = Z*PQ/d
2
 
        Where 
        Z = 95% confidence limits 
        d = precision of 5% 
        P = incidence of 21% 
 
Reference : 
Kim YS, Yun HJ, Shim SK, Koo SH, KimSY, Kim S. A Comparative trial 
of a single dose of azithromycin versus doxycycline for the treatment of 
mild scrub typhus. Clinical Infectious Diseases 2004; 39:1329–35. Where 
incidence was found to be 21%. 
      
 
 
STATISTICAL METHODS 
 
Data entry was done using the Microsoft excel software and analysis was done using 
Statistical Package for the Social Sciences (SPSS) software package (version 15). 
Descriptive statistics were calculated using SPSS software. Chi-square test was used 
for comparison of categorical variables. Odds ratio (OR) and confidence intervals (CI) 
were calculated and a ‘p’ value less than 0.05 was considered statistically significant. 
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All reported p values are two-sided. Univariate analysis such as Independent t-test and 
Mann Whitney U test, Kruskall Wallis tests were performed to assess the risk factors 
for clinical outcome among the study patients. Logistic regression was done to look 
for combined significance of the variables. 
 
 
Ethics committee clearance and funding: 
The study design and methods were approved by the Fluid Research Committee, 
Christian Medical College Vellore. 
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RESULTS 
This prospective observational cohort study was conducted from November 2013 to 
January 2015. During this period 241 patients were screened for scrub typhus, of 
which eighteen were excluded. Ten of them had dengue, four had urinary tract 
infection, two had malaria and two had respiratory tract infection. 
 Two hundred and twenty three (n=223) satisfied the inclusion criteria for scrub 
typhus and were included in the study (strobe statement-figure 15). 
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Figure 15: STROBE STATEMENT-STUDY FLOW CHART 
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BASELINE CHARACTERISTICS 
 
 
Demographic features of patients with scrub typhus 
 
Table 5: Demographic features of patients with scrub typhus(N=223) 
Variable  Frequency(N=223)  Percentage (%)  
Demographics  
Mean age in years, Mean (SD)  47.6 (15.1)  
Sex 
Male  102  45.7%  
Female  121  54.3%  
Occupation  
House wife  119  53.4%  
Manual labourer  49  22% 
Farmer  37  16.6% 
Student  9  4% 
Business  9  4%  
State   
Tamil Nadu  165  74% 
Andhra Pradesh  54  24.2% 
West Bengal  3  1.3% 
Karnataka  1  0.4% 
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 Demographic characteristics  
The study cohort comprised of 223 patients with the most common age group of 40-
60 years (figure 2), mean age 47.6 ±15.12years. There was female preponderance with 
54.3% females and 45.7% males. The patients were predominantly from Tamil Nadu 
74% (n=165) followed by 24.2% from Andhra Pradesh, 1.3% were from west Bengal 
and 0.5% from Karnataka (figure 16). 
 
The majority of subjects were house wives 53.4%, followed by manual laborers 
(22%), farmers (16.6%), businessmen and students were 4% each (Table 5). 
 
 Co-morbidities 
The predominant co-morbidity was diabetes mellitus which was seen in 10.3% (n=23) 
followed by hypertension (9%), cerebrovascular accident (0.9%), ischemic heart 
disease (0.9%), chronic liver disease (1.3%), alcoholism (2.7%), COPD (0.9%) and 
pregnancy (2.7%). 
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Figure 16: Age distribution in patients with scrub typhus (N-223)  
 
 
 
 
Figure 17: Gender distribution in patients with scrub typhus (N-223) 
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Figure 18: State wise distribution in patients with scrub typhus (n-223) 
 
 
 
Figure 19: Occupation distribution of patients with scrub typhus (N-223) 
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Table 4: Clinical characteristics in patients with scrub typhus 
 
 
Table 4:Clinical features in patients with scrub typhus (N=223) 
Symptoms Frequency n (%) 
Chills 216 (96.9) 
Breathlessness 197 (88.3) 
Myalgia 121 (54.7) 
Cough 99 (44.4) 
Headache 64 (28.7) 
Altered Sensorium 64 (28.7) 
Vomiting 48 (21.5) 
Seizures 6 (2.7) 
Bleeding 5 (2.2) 
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 Clinical signs in patients with Scrub Typhus (N=223) 
 
Table 5:Clinical signs in patients with Scrub Typhus (N=223) 
Signs Frequency 
Pulse,  Mean ±SD 109.3  ± 19.59 
Systolic BP, Mean ±SD 105  ± 19.76 
Diastolic BP Mean ±SD 66.5  ± 12.55 
Respiratory rate, Mean ±SD 31.5  ± 10.30 
Crepitations, n (%) 183 (82.1) 
Eschar Positive, n (%) 161 (72.2) 
Desaturation, n (%) 112 (50.2) 
Hepatomegaly, n (%) 14 (6.3) 
Splenomegaly, n (%) 2 (0.9) 
All the patients in this cohort had fever as the presenting complaint, followed by 
breathlessness in 88.3%, myalgia (54.7%), cough (44.4%), headache (28.7%), altered 
sensorium (28.7%), vomiting (21.5%) and bleeding and seizures in 2.2% and 2.7% of 
patients respectively (Table 4). 
The mean pulse rate was 109.3 ± 19.59 per minute; the systolic and diastolic blood 
pressures were 105 ±19.76 mm of hg, 66.5 ±12.55 mm of hg respectively. Eschar was 
seen in 72.2% of the patients, with the most common site being axilla (n=45, 17.5%) 
followed by back (13.5%), groin (11.7%), chest (9.9%), abdomen (5.8%) and trunk 
(5.8%, Figure 1). The predominant sign was crepitation which was seen in 82.1% of 
the subjects followed by desaturation (50.2%), hepatomegaly (6.3%), and 
splenomegaly (0.9%)  (Table 5)   
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Figure 20: Presence of Eschar in patients with Scrub Typhus (N=223) 
 
 
 
Figure 21:  Site of Eschar in patients with Scrub Typhus (N=223) 
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 Baseline characteristics in the three antibiotic arms  
Table 6:Baseline characteristics between the three antibiotic arms (N=223) 
Variable 
Doxycycline 
group 
(n=63), 
n(%) 
Azithromycin 
group 
(n=64), 
n(%) 
Doxycycline + Azithromycin 
group 
(n=96) 
n(%) 
P  value 
Demographics 
Male 36(57.2%) 26(40.6%) 40(41.6%) 0.099 
Female 27(42.8%) 38(59.4%) 56(58.4%)  
Clinical Features 
 Duration of 
illness, days, 
mean(SD) 8.09(3.6) 8.75(4.5) 8.21(4) 0.104 
Chills 61(96.8%) 64(100%) 91(94.8%) 0.180 
Breathlessnes 46(73%) 58(90.6%) 93(96.8%) <0.001 
Myalgia 43(68.2%) 30(46.9%) 48(50%) 0.029 
Cough 26(41.2%) 31(48.4%) 42(43.7%) 0.709 
Headache 24(38%) 15(23.4%) 25(26%) 0.141 
Vomiting 12(19%) 13(20.3%) 23(23.9%) 0.733 
Abdomen 
pain 
8(12.7%) 7(10.9%) 12(12.5%) 0.943 
Seizures 1(1.58%) 1(1.5%) 4(4.1%) 0.496 
Co-morbities 
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In this cohort, there was an increased proportion of males in doxycycline arm (57.2%), 
more females in azithromycin arm (59.4%).  
The duration of fever at presentation was least in the doxycycline group with mean of 
8.1 days and highest in the azithromycin group with a mean of 8.7 days (p value 
0.104). All the patients had fever with the most common associated feature being 
chills, followed by myalgia. It was seen maximum in doxycycline group (68.2%). 
Cough was the third common symptom, more commonly seen in azithromycin group 
(48.4%). The other clinical features were headache, vomiting abdominal pain and 
seizures. Seizures were more common in the combined group of azithromycin and 
doxycycline group.  
Diabetes mellitus was seen in all the three groups, seen in 12.7% in doxycycline 
group, 10.4% in the combined group of azithromycin and doxycycline group. Scrub 
Table 6- Baseline characteristics between the three antibiotic arms (continued) 
Variable 
Doxycycline 
group 
(n=63), 
n(%) 
Azithromycin 
group 
(n=64), 
n(%) 
Doxycycline + Azithromycin 
group 
(n=96) 
n(%) 
P  value 
Diabetes 
Mellitus 8(12.7%) 5(7.8%) 10(10.4%) 0.731 
Hypertension 5(7.9%) 6(9.3%) 9(9.3%) 0.944 
Pregnancy 0 5(7.8%) 1(1.04%) 0.010 
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IgM was positive in 82.8% in the azithromycin group, 77.1% in the combined group 
and 73% in the doxycycline group. (Table 6) 
 Laboratory characteristics in patients with Scrub Typhus 
Table 7:Laboratory features of patients with Scrub Typhus (N=223) 
Variable(N=223) Frequency, mean± SD 
Hemoglobin  gm/dl 11.8 ± 2.34 
Total leukocyte count, cells/mm
3
 11,957 ±5450.9 
Neutrophils% 74.74 ±11.3 
Lymphocytes% 17.95 ±10.9 
Platelets cells/mm
3
 84,904 ±75489.4 
Creatinine mg/dl  1.5 ±1.1 
Urea  mg/dl 61.09 ±50.6 
Total bilirubin mg/dl  1.94 ±2.2 
Direct Bilirubin mg/dl 1.60 ±2.1 
Total Protein gm/dl 6.3 ±0.9 
Albumin gm/dl 2.75 ±0.6 
SGOT* IU/L 139.7 ±151.1 
SGPT* IU/L 72 ±61.8 
ALP* IU/L 187 ±131.6 
Bicarbonate mmol/dl 19.05 ±4.8 
*SGOT- Serum glutamic oxaloacetic transaminase, SGPT- Serum glutamic pyruvic 
transaminase, ALP- Alkaline phosphatase 
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The mean hemoglobin was 11.8mg/dl±2.34 with the mean leukocyte counts of 
11,957±5450.9 cells/mm
3
, with neutrophils of 74.74+11.33 cells/mm
3
. 
Thrombocytopenia was a common feature of scrub typhus with mean platelet counts 
of 84,904+ 75,489 cells/mm
3
 (Table 7). 
The mean creatinine was 1.5+1.14mg/dl, mean urea of 61.09+50.59 mg/dl, liver 
function tests were derranged with mean total bilirubin of 1.94+2.18 mg/dl, mean 
albumin of 2.75+0.625 mg/dl, mean SGOT and SGPT was 139.7+151.12 mg/dl and 
72+61.86 mg/dl respectively, the mean alkaline phosphatase was 187+131.61 mg/dl. 
Scrub IgM Elisa was positive in 79.4% of the patients with scrub typhus (Figure 22). 
 
Figure 22: Scrub Typhus IgM ELISA positive in patients with Scrub Typhus 
 
n-177 
n-46 
Scrub IgM postivity (N-223) 
Positive (79.4%)  Eschar only(20.6%)  
 80 | P a g e  
 
 
 Comparison of laboratory parameters in the three antibiotic 
groups 
Table 8:Laboratory variables between the three antibiotic groups (N=223) 
Variable 
Doxy 
n=63,  
mean (SD) 
Azithromycin 
n=64,  
mean (SD) 
Doxycycline+Azithrom
ycin, n=96, 
mean (SD) 
P  value 
Haemoglobin gm/dl  12.3(1.93) 11.15(2.4) 11.8(2.4) 0.024 
TLC* cells/mm
3
  10972(5906) 11386(4581) 12973(5559) 0.023 
Neutrophils % 71.73(12.3) 75.84(13.06) 75.95(10.5) 0.073 
Lymphocytes% 19.97(10.7) 17.91(12.6) 16.67(9.6) 0.147 
Platelet count 
cells/mm
3
 
99501(94815) 79093(65551) 79197(66143) 0.367 
Creatinine mg/dL 1.16(0.8) 1.50(1.1) 1.72(1.2) 0.024 
Urea mg/dL 43.50(32.6) 61.12(40.3) 71.28(61.6) 0.004 
Total Bilirubin mg/dL 1.25(1.7) 2.18(2.6) 2.30(2) <0.001 
Direct Bilirubin mg/d 0.86(1.5) 2(2.9) 1.82(1.7) <0.001 
Protein gm/dL 6.73(0.8) 6.12(1.1) 6.1(0.82) 0.996 
Albumin gm/dL 3.08(0.5) 2.63(0.5) 2.62(0.64) <0.001 
SGPT*  IU/L 104.4(72.5) 132.6(89.1) 167.5(207.4) 0.009 
SGOT* IU/L 73.4(66.9) 73.8(60.1) 70.2(60.1) 0.745 
ALP* IU/L 132.8(84.5) 217.3(163.7) 201.3(122.9) <0.001 
Bicarbonate mmol/L 20.6(4.1) 20(4.5) 18.08(5.1) 0.006 
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Table 8-Laboratory variable between the three antibiotic groups (continued) 
Variable 
Doxy 
n=63,  
mean (SD) 
Azithromycin 
n=64,  
mean (SD) 
Doxycycline+Azithrom
ycin, n=96, 
mean (SD) 
P  value 
Scrub IgM positive 
n=177, (%) 
46(73%) 57(82.8%) 74(77.1%) 0.063 
SOFA* 3.60(2.3) 6.67(4.7) 8.26(5.2) <0.001 
*TLC-total leukocyte count, SGOT- Serum glutamic oxaloacetic transaminase, SGPT- Serum glutamic pyruvic 
transaminase, ALP- Alkaline phosphatase, SOFA- Sequential Organ Failure Assessment 
 
The comparison of the three groups showed that the hemoglobin level was higher in 
the doxycycline group with a mean of 12.37±1.93 mg/dl, the total counts was higher 
in the combined group of doxycycline and azithromycin with a mean of 12,973 
cells/mm
3
 (p value 0.024) . Thrombocytopenia was seen in all the three groups of the 
study with maximum thrombocytopenia seen in the azithromycin group (mean of 
79,093cells/mm
3
).  Renal dysfunction was seen in two groups namely azithromycin 
and the combined group of doxycycline and azithromycin groups, with the maximum 
dysfunction seen in the combined group with creatinine of 1.72mg/dl. Hepatic 
dysfunction was highest in the combined group of azithromycin and doxycycline with 
total bilirubin of 2.30mg/dl, albumin of 2.62mg/dl, SGOT of 167.5U/L, SGPT of 
70.2U/L, and alkaline phosphatase of 201.3IU/L.  
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 Organ dysfunction in patients with scrub typhus(4) 
Table 9: Organ dysfunction in patients with scrub typhus (N-223) 
Organ involved Frequency n(%) 
Central nervous system involvement (altered sensorium) 64 (28.7%) 
Cardiovascular dysfunction  (BP<80mmhg) 24 (10.8%) 
Respiratory dysfunction (SPO2<90) 112 (50%) 
Hematological dysfunction 
Anemia (Hb<12gm/dl) 116 (52%) 
Thrombocytopenia(<1lakh/mm
3
) 150 (67.2%) 
Hepatic dysfunction 
Elevated bilirubin (>2mg/dl) 44(19.7%) 
SGOT (>3time 120IU/L) 92 (41.2%) 
SGPT (>3 time 105IU/L) 38 (17%) 
ALP (>140IU/L) 129 (57.8%) 
Albumin (<3.5mg/dl) 198 (88.8%) 
Renal dysfunction (Creatinine >2mg/dl) 46 (20.6%) 
*TLC-total leukocyte count, SGOT- Serum glutamic oxaloacetic transaminase, SGPT- Serum glutamic pyruvic 
transaminase, ALP- Alkaline phosphatase 
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 Organ dysfunction in antibiotic groups 
Table 10: Organ dysfunction in antibiotic groups 
Organ dysfunction Doxycycline  
n=63, n (%) 
Azithromycin 
 n=64, n (%) 
Doxy + azithro 
n=96, n (%)  
Central nervous system dysfunction 
(altered sensorium) 
3(4.8%) 18 (28.1) 43 (44.8%) 
Hemodynamic dysfunction 
(BP<80mmhg) 
3(4.7%) 6(9.3%) 15(15.6%) 
Respiratory dysfunction (SPO2<90) 36(57.1%) 26(40.6%) 50(52.1%) 
Hematological dysfunction    
Anemia (Hb<12gm/dl) 29(46%) 38(59.4%) 49(51%) 
Thrombocytopenia(<1lakh/mm
3
)  42(66.6%) 45(70.3%) 63(65.6%) 
Hepatic dysfunction 
Elevated bilirubin (>2mg/dl) 5(7.9%) 11(17.1%) 28(29.1%) 
SGOT (>3 times 120IU/L) 22(34.9%) 28(43.7%) 42(43.7%) 
SGPT (>3 times, 105IU/L) 12(19%) 11(17%) 15(15.6%) 
ALP(>125IU/L) 22(34.4%) 42(65.6%) 65(67.7%) 
Albumin (<3.5mg/dl) 46(73.8%) 61(95.3%) 91(94.8%) 
Renal dysfunction (Creat>2mg/dl) 4(6.3%) 14(21.8%) 28(29.1%) 
*TLC-total leukocyte count, SGOT- Serum glutamic oxaloacetic transaminase, SGPT- Serum glutamic pyruvic 
transaminase, ALP- Alkaline phosphatase. 
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Table 11:Number of organs involved in patients with scrub typhus (N=223) 
Number of organs involved (n) Frequency, n (%) 
0 12 (5.4) 
1 40 (17.9) 
2 82 (36.8) 
3 51 (22.9) 
4 29 (13) 
5 8 (3.6) 
6 1 (0.4) 
 
 
 
The most common organ dysfunction in our cohort was hematological dysfunction 
followed by respiratory and hepatic dysfunction. The central nervous system and renal 
dysfunction were more severe in the combined group; respiratory dysfunction was 
more common in the doxycycline group. Two organ systems were commonly 
involved (36.8%). 
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OUTCOMES 
 
Primary Outcome in patients with scrub typhus 
 
 
 
Table 12: Primary outcome, Incidence of delayed defervescence in patients 
with scrub typhus (N=223) 
Variable 
Doxycycline 
 
n- 63 
Azithromycin  
 
n- 64 
Doxycycline+ 
Azithromycin 
n-96 
 
Mean duration of 
fever defervescence, 
hours (SD) 
31.40(20.9) 38.03(28.8) 37.10(22.8) 
P value- 
0.257 
Delayed fever 
defervescence 
(>48hrs), mean (%) 
10 (15.9) 18 (28.1) 27 (28.1) 
Total=55 
(24.66%) 
Fever defervescence 
(<48 hrs), mean (%) 
53 (84.1) 46 (71.9) 69 (71.9) 
Total=168 
(75.64%) 
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Figure 23: Primary outcome- delayed defervescence in patients with scrub 
typhus. 
 
 
The primary outcome was incidence of delayed defervescence which was defined as 
the duration of fever defervescence of more than 48 hours after the initiation of 
antibiotics in patients presenting with scrub typhus. The mean duration of fever 
defervescence in the three groups, doxycycline, Azithromycin and the combined 
group of doxycycline and Azithromycin group was 31.40 hrs, 38.04 hrs, 37.10 hrs 
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scrub typhus presenting to the hospital was 24.66% (n=55). The number of patients 
with delayed defervescence was lowest in doxycycline group 15.9% (n=10).  
(Table 12) 
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Secondary outcomes 
 
Subgroup analysis was done to the patients to look at the secondary outcomes which 
showed the following. 
 Factors associated with delayed defervescence (Univariate 
analysis). 
Table 13: Comparison between early and delayed defervescence group in all 
the patients with Scrub typhus (n=223) 
Variable  
 
(n=223) 
Delayed defervescence 
>48 hours 
(n=55) 
Fever defervescence 
 < 48hours 
(n=168) 
P value 
Sex n (%) n (%)  
Male 24(43.6%) 78(43.6%) 
0.718 
Female 31(56.3%) 90(53.6%) 
Clinical features    
Duration of illness,  days (SD) 7.98(3.6) 8.45(4.2) 0.922 
Breathlessness (%) 52(94.4%) 145(86.3%) 0.145 
Diabetes mellitus (%) 5(9.09%) 18(10.7%) 0.731 
Laboratory parameters Mean (SD) Mean(SD)  
Haemoglobin gm/dl  11.9(2.3) 11.7(2.3) 0.575 
TLC* /mm
3
 11670(5741) 12051(5366) 0.398 
Platelets cells/mm
3
  69729(58071) 89872(9801) 0.102 
Creatinine mg/dl  1.3(0.9) 1.5(1.2) 0.446 
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Table 13- Comparison between early and delayed defervescence group in all the patients 
with scrub typhus (continued) 
Variable  
 
(n=223) 
Delayed defervescence 
>48 hours 
(n=55) 
Fever defervescence 
 < 48hours 
(n=168) 
P value 
Total bilirubin mg/dl  1.9(2.3) 1.9(2.1) 0.698 
Albumin gm/dl 2.8(0.5) 2.7(0.6) 0.549 
SGOT * IU/L 141.7(91.5) 139(166.3) 0.134 
SGPT*  IU/L  68.4(37.8) 73.3(67.9) 0.514 
ALP* IU/L  185.4(128.5) 187.5(132.9) 0.897 
Bicarbonate mmol/dl  19.6(4.1) 18.8(5) 0.383 
SOFA score 7.1(4.9) 6.28(4.8) 0.215 
*TLC-total leukocyte count, SGOT- Serum glutamic oxaloacetic transaminase, SGPT- Serum 
glutamic pyruvic transaminase, ALP- Alkaline phosphatase, SOFA- Sequential Organ Failure 
Assessment 
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 Organ dysfunction versus delayed defervescence (Univariate 
analysis) 
 
 
 
 
 
 
Table 14: Comparison of organ dysfunction versus defervescence in patients 
with Scrub typhus (Univariate analysis, N=223) 
Variable  
 
(n=223) 
Delayed defervescence 
>48 hours 
(n=55), Mean(SD) 
Fever defervescence 
 < 48hours 
(n=168), Mean (SD) 
P value 
Duration of hypotension, day 0.74(1.8) 0.41(0.9) 0.45 
Duration of inotropes, days 0.69(1.8) 0.36(0.9) 0.51 
Duration of oxygen, days 3(3.3) 1.6(2.4) 0.01 
Duration of NIV, days 0.4(1.1) 0.2(0.8) 0.36 
Duration of IV, days 1.7(3.4) 0.9(2.2) 0.19 
Duration of ventilator, days  2.1(3.5) 1.2(2.3) 0.07 
Duration of  altered 
sensorium, days 1.7(3.3) 1(2.1) 0.56 
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 Logistic regression  
 
 Comparison between the number of organs involved and 
delayed defervescence 
Table 16: Comparison between the number of organs involved and delayed 
defervescence 
Organs involved 
 
Early 
defervescence, 
n %) 
Delayed 
defervescence,  
n (%) 
 
Odds ratio-14.58, 
95% C.I.- (6.71-
32.86) 
P value-<0.001. 
>2 organs 43 (25.6) 46 (83.6) 
≤ 2 organs 125 (74.4) 9 (16.3) 
 
Table 15: Logistic regression of significant variables 
Variable  (n=223) Significance- p Value  
Duration of fever  0.457 
Breathlessness  0.099 
SOFA score 0.272 
Platelet count  0.085 
Duration of oxygen (days) 0.001 
Duration of ventilator (days) 0.020 
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Univariate analysis of baseline characteristics showed that the respiratory system 
involvement in the form of duration of oxygen required and duration of ventilator 
required were statistically significant with respect to the primary outcome. Logistic 
regression done for the factors that were trending towards significance which did not 
show statistical significance showed that respiratory system involvement in the form 
of increasing duration of oxygen and duration of ventilator days had increasing 
incidence of delayed defervescence (p value 0.001 & 0.020). It was also seen that the 
incidence of delayed defervescence increased when more than 2 organ systems were 
involved (83.3%, p value <0.001) with odds ratio of 14.58 (6.71-32.86). 
 
 Duration of organ recovery 
Table 17: Comparison between antibiotic groups for organ recovery (N=223) 
Variable 
Doxycycline 
(n=63), 
mean(SD) 
Azithromycin 
(n=64), 
mean(SD) 
Doxycycline+Azithrom
ycin (n=96),  
mean(SD) 
P value 
SOFA * 3.60(2.3) 6.67(4.6) 8.26(5.2) <0.001 
Duration hospital stay days 4.16(2.7) 6.97(3.6) 6.51(3.6) <0.001 
Duration of hypotension days 0.05(0.21) 0.50(1.09) 0.79(1.6) <0.001 
Duration of  Inotrope days 0 0.47(1.05) 0.72(1.6) <0.001 
Duration of Oxygen days 0.38(1.09) 1.75(2.5) 3.10(3.09) <0.001 
Duration of NIV* days 0.16(0.8) 0.30(0.8) 0.45(1.05) <0.001 
Duration of IV* days 0.06(0.5) 1.00(2.3) 1.88(3.2) <0.001 
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The combined group of Doxycycline and Azithromycin had patients with severe 
illness as evidenced by SOFA (sequential organ failure assessment) score of 8.26, 
Doxy group and Azithromycin groups had SOFA score were 3.60 and 6.67 
respectively. The total hospital stay days was longer in Azithromycin group with 
mean duration of 6.97 days, doxy and Azithromycin group were 4.16 and 6.51 days 
respectively (p <0.001). The total days of hypotension was longest in the 0.79 days (p 
value <0.001) combined group of Doxycycline and Azithromycin group, the total 
inotrope days were higher in the combined group of Doxycycline and Azithromycin 
group with a mean of 0.72days (p value <0.001). 
Table 17-Comparison between antibiotic groups for organ recovery (continued) 
Variable 
Doxycycline 
(n=63), 
mean(SD) 
Azithromycin 
(n=64), 
mean(SD) 
Doxycycline+Azithrom
ycin (n=96),  
mean(SD) 
P value 
Duration of Low altered 
sensorium* days 
0.10(0.5) 1.11(2.3) 2.06(3.09) <0.001 
Duration of creatinine >2mg/dl, 
days 
0.25(0.9) 0.86(2) 1.15(2.1) 0.003 
Duration of bilirubin >2mg/dl, 
days 
0.44(1.3) 1.56(2.6) 1.74(2.3) 0.001 
*SOFA- Sequential Organ Failure Assessment, NIV- non invasive ventilation, IV- invasive ventilation, GCS- Glasgow coma 
scale 
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The oxygen requirement was maximum in the combined doxycycline and 
Azithromycin group with a mean of 3.10days (p value <0.001). The requirement of 
mechanical ventilation with non invasive ventilation (NIV) and invasive ventilation 
(IV) was highest in the combined antibiotic group of doxycycline and Azithromycin 
group with a mean duration of 0.45 days and 1.88 days respectively (p< 0.001). 
The sensorium took longer to recover in the combined group of doxycycline and 
Azithromycin with a mean of 2.07days (p <0.001) of total reduced GCS (Glasgow 
coma scale) days. 
The renal failure took longer to recover in the combined group of Azithromycin and 
Doxycycline group with mean of 1.15days (p 0.003).The total days of elevated 
bilirubin of more than 2mg/dl was higher in the combined group of Azithromycin and 
Doxycycline group with a mean duration of 1.74days (p 0.001) (Table 19). 
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Figure 24: Crude mortality rate in patients with scrub typhus 
 
 
 
There were a total of 11 deaths in the cohort with a crude mortality rate of 4.9%, with 
7 in the combined group and 4 in the azithromycin only group, 5 were discharged 
against medical advice (DAMA). 
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Results in critically ill patients 
 Baseline characteristics in critically ill patients (ICU) 
Table 18:Baseline characteristics of critically ill patients (N=56) 
Variable (n=56) Frequency (mean ± SD) 
Duration of fever, days 9.46±8.98 
SOFA Score 12.91±4.33 
Pulse /min 118.5± 23.11 
Systolic Blood Pressure mm of Hg 102.32 ±23.19 
Diastolic Blood Pressure mm of Hg 63.04 ±15.00 
Respiratory Rate /min 38.48 ±10.35 
Laboratory parameters Frequency (mean ± SD) 
Haemoglobin gm/dl 11.42 ±2.84 
TLC* cell/mm
3
 13001 ±5668.60 
Neutrophils (%) 77.25 ±12.53 
Lymphocytes (%) 17.02 ± 11.56 
Platelets cell/mm
3  
 55,535 ± 49335.57 
Creatinine mg/dL 
2.07 ± 1.42 
Total bilirubin mg/dL 
2.74 ± 2.47 
Direct bilirubin mg/dL 
2.205 ±2.21 
Total Protein g/dL 
6.664 ±6.09 
Albumin g/dL 
2.50 ±0.716 
SGOT* IU/L 
179.48± 134.28 
SGPT*IU/L 
63.82 ±43.43 
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Table 18- Baseline characteristics of critically ill patients (continued) 
Variable (n=56) Frequency (mean ± SD) 
ALP*  IU/L 
234.68 ±129.04 
Bicarbonate mmol/L 
15.82 ±4.63 
*TLC-total leukocyte count, SGOT- Serum glutamic oxaloacetic transaminase, SGPT- Serum glutamic pyruvic 
transaminase, ALP- Alkaline phosphatase. 
 
There were 56 subjects requiring critical care. The mean duration of fever at 
presentation was 9.46±8.98 days. The mean pulse rate was 118.5±23.11 bpm, mean 
systolic blood pressure was 102.32 mm of hg (SD 23), mean diastolic blood pressure 
was 63.04 mm of hg (SD15), mean respiratory rate was 38.48 per minute (SD 10.35) 
(Table 20). 
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 Laboratory parameters in critically ill patients 
Table 19:Comparison of laboratory parameters in the three antibiotic groups 
in critically ill subjects (N=56) 
Variable (n=56) 
Doxycycline 
(n=2), 
mean(SD) 
Azithromycin 
(n=15) , 
mean(SD) 
Doxycycline 
+Azithromycin 
(n=39) , mean(SD) 
 P value 
SOFA score 10.50(7.7) 12.80(5) 13.08(3.9) 0.852 
Haemoglobin g/dl  9.9(0.9) 11.4(1.9) 11.5(3.1) 0.388 
TLC* cell/mm
3
 17,500(2404) 10109(4889) 13883(5690) 0.029 
Neutrophils % 75.5(14.8) 80.3(13.3) 76.2(12.3) 0.324 
Platelet count cell/mm
3
 38,500(20506) 66,000(44357) 52,384(52136) 0.218 
Creatinine mg/dl 2.13(1.8) 2.20(1.6) 2.02(1.3) 0.920 
Total Bilirubin mg/dl 1.75(1.5) 3.34(3.8) 2.56(1.8) 0.907 
Albumin g/dl 2.30(0.1) 2.31(0.4) 2.58(0.8) 0.320 
SGOT* IU/L 110.00(38.2) 167.4(107.8) 187.69(146.2) 0.772 
SGPT * IU/L 20.00(5.6) 73.20(39.4) 62.46(44.9) 0.053 
ALP* IU/L 216.00(53.7) 229.80(109.7) 237.51(139.8) 0.996 
Bicarbonate mmol/L 14.00(8.5) 15.13(3.2) 16.17(4.9) 0.622 
*TLC-total leukocyte count, SGOT- Serum glutamic oxaloacetic transaminase, SGPT- Serum glutamic pyruvic 
transaminase, ALP- Alkaline phosphatase. 
 
The mean hemoglobin was 11.42 + 2.84 mg/dl, mean total count 13001±5668.6 
cells/mm
3
, and mean platelet count was 55,535+49335.5 cells/mm
3
.The mean 
creatinine value in critically ill patients was 2.07±1.42 mg/dl, mean total bilirubin was 
2.74±2.47mg/dl, mean albumin was 2.50±0.716mg/dl, there was evidence of hepatitis 
with elevated liver enzymes, with mean SGOT and SGPT of 179.48±134.28U/L and 
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63.82+43.43U/L respectively and the mean alkaline phosphatase level was 
234.68+129.04U/L. The patients were generally severely ill with higher mean SOFA 
score levels were 12.91+4.33. 
The hemoglobin was least in the doxycycline group with a mean value of 9.90gm/dl 
(p value 0.388), total counts was maximum in the doxycycline group with a mean 
value of 17,500cells/mm
3
 (p value 0.029), thrombocytopenia was seen in all the three 
groups with lowest platelet levels in the doxycycline group with mean value of 
38,500cells/mm
3
 (p value of 0.218). Renal dysfunction was maximum in the 
azithromycin group with mean creatinine of 2.20mg/dl (p value 0.920); hepatic 
dysfunction was maximum in the azithromycin group with a mean total bilirubin of 
3.34 mg/dl (p value 0.907), transaminitis was severe in the combined group of 
azithromycin and doxycycline group with a mean SGOT and SGPT of 187.69 U/L (p 
value 0.772) and 62.46 U/L (p value 0.053) respectively. The general severity of the 
disease was more in the combined group of azithromycin and doxycycline with a 
mean SOFA of 13.08 (p value of 0.852).   
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Table 20: Organ dysfunction in critically ill patients 
Organ dysfunction 
Monotherapy (Doxy or 
azithromycin, 
N=17, n (%) 
Dual therapy (Doxy + 
azithro) 
 N=39, n (%) 
Central nervous system 
dysfunction(altered sensorium) 
14 (82.3%) 29(74.3%) 
Hemodynamic dysfunction 
(BP<80mmhg) 
2(11.7%) 10(25.6%) 
Respiratory dysfunction (SPO<90%) 10(58.8%) 15(38.4%) 
Hematological dysfunction 
Anemia (Hb<12gm/dl) 10(58.8%) 31(79.4%) 
Thrombocytopenia(<1lakh/mm
3
)  17(100%) 32(82.05%) 
Hepatic dysfunction 
Elevated bilirubin (>2mg/dl) 9(52.9%) 12(30.7%) 
SGOT (>3times 120IU/L) 12(70.6%) 10(25.6%) 
SGPT (>3times 105IU/L) 5(29.4%) 8(20.5%) 
Alkaline phosphatase (>125IU/L) 12(70.6%) 27(69.2%) 
Albumin (<3.5mg/dl) 15(88.23%) 33(84.6%) 
Renal dysfunction (Creat>2mg/dl) 9(52.9%) 22 (56.4%) 
 
The organ system involvement was similar in both the monotherapy and combination 
therapy arms. Central nervous system, hematological and hepatic involvement was 
more seen in the monotherapy arm, renal dysfunction was seen in the combination 
group. 
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 Outcomes in critically ill subjects 
Primary outcome in critically ill patients 
Table 21:Incidence of delayed defervescence in critically ill patients with Scrub 
Typhus(n=223) 
Variable (N= 56) 
Doxycycline  
 
(n=2)  
Azithromycin  
 
(n=15)  
Doxycycline+Azithro
mycin  
(n=39)  
 
Duration of fever 
defervescence, hours. 
 mean (SD) 
9(11.3) 37.20(36) 37.15(23.9) 
P value- 
0.248 
Delayed defervescence 
>48hrs, n (%) 
0 4 (26.7) 12 (31.6) 16(28.6%) 
  
The primary outcome, incidence of delayed defervescence in critically ill patients was 
28.6% (n=16) (p value 0.248). The mean duration of fever defervescence in 
doxycycline group was the lowest with a mean of 9 hours, defervescence in 
Azithromycin and the combined doxycycline and Azithromycin group was 37.20hrs 
and 36.15 hrs respectively (p value 0.248). The incidence of delayed defervescence 
was highest in the combined group of doxycycline and Azithromycin, 21.40% (n=12). 
(Table 21) 
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Secondary outcomes in critically ill patients 
 Comparison between early and delayed defervescence groups in critically ill 
patients with scrub typhus(Univariate analysis) 
Table 22: Comparison between early and delayed defervescence groups in 
critically ill patients with scrub typhus (N=56) 
Variable 
(n-56) 
Fever defervescence 
<48hrs 
n=40, mean(SD) 
Delayed defervescence 
>48 hrs 
n=16, mean(SD) 
P Value 
Duration of illness, days 9.98(10.5) 8.19(2.7) 0.822 
SOFA* score 12.55(4.4) 13.81(4.1) 0.30 
Pulse /min 117.70(23.2) 120.69(25.7) 0.84 
SBP* mmHg 99.75(20.8) 108.75(23.3) 0.95 
RR* /min 38.78(11.8) 37.75(8) 0.87 
Haemoglobin gm%  11.43(2.5) 11.38(2.4) 0.90 
TLC* cells/mm
3
 13037(5963) 12913(5140) 0.73 
Neutrophils % 77.68(11.4) 76.19(14.2) 0.95 
Platelets cells/ mm
3
 53625(42126) 60312(54763) 0.69 
Creatinine mg/dl 2.14(1.4) 1.38(1.3) 0.47 
Total bilirubin mg/dl 2.66(2.1) 2.94(3.4) 0.72 
Albumin gm/dl 2.48(0.8) 2.55(0.39) 0.19 
SGOT* IU/L 178.88(105.4) 181.00(80.1) 0.67 
SGPT* IU/L 62.28(57.7) 67.69(39.6) 0.44 
ALP* IU/L 229.73(103.9) 247.06(161.2) 0.80 
Bicarbonate mmol/L 15.34(4.5) 17.01(4.55) 0.26 
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The mean pulse rate was highest in the delayed defervescence group with a mean of 
120.69 /min when compared to the early defervescence group which was 117.70 /min. 
The blood pressure at presentation was highest in the delayed defervescence group 
with mean systolic blood pressure of 108.75mmhg (Table 22). The duration of initial 
presentation of fever was least in the delayed defervescence group with a mean of 
8.19 days. Renal dysfunction was the highest in the early defervescence group with a 
mean creatinine of 2.14 mg/dl (p value 0.47). The alkaline phosphatase and SGOT 
values were higher in the delayed defervescence group 247.06 U/L (p value 0.67) and 
181 U/L (p value 0.44) respectively.  
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 Duration of organ recovery in critically ill patients with scrub 
typhus 
Table 23:Comparison between the antibiotic groups for organ recovery in critically ill 
patients (N=56) 
Variable 
(n-56) 
Monotherapy (Doxy 
or azithromycin)  
n=17, mean(SD) 
Doxycycline+Azithrom
ycin  
n=39 , mean(SD) 
P  value 
SOFA* score 12.52(5.1) 13.08(3.9) 0.077 
Duration of ICU* days 4.76(3.3) 5.36(2.9) 0.471 
Total duration of hospital admission day 8.23(3.9) 9.10(3.9) 0.745 
Total duration of Hypotension, days 1.41(1.4) 1.85(2.2) 0.163 
Total duration of Inotrope, days 1.29(1.3) 1.62(1.6) 0.249 
Total duration of oxygen, days 5(2.6) 5.54(2.9) 0.111 
Total duration of low p/f* days  4.7(2.8) 5.54(2.9) 0.443 
Total duration of altered sensorium, day 3.76(3.2) 4.77(3.2) 0.794 
Duration of NIV*, days 1(1.9) 0.67(1.3) 0.085 
Duration of IV*, days 3.52(3.3) 4.64(3.6) 0.848 
*SOFA- Sequential Organ Failure Assessment, ICU-intensive care unit, p/f –PaO2/FiO2, GCS- Glasgow coma scale, NIV- non 
invasive ventilation, IV- invasive ventilation. 
 
The combined group of doxycycline and azithromycin group had patients with severe 
illness with a mean SOFA score of 13.08, with doxycycline and azithromycin groups 
having SOFA scores of 10.50 and 12.80 respectively (p value 0.852). The combined 
group of doxycycline and azithromycin group had shorter mean ICU days of 5.36 days 
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compared to doxycycline group with mean of 7 days (p value 0.471). The total 
hypotension days was longer in combined group of doxycycline and azithromycin 
group with a mean of 1.85 days compared to azithromycin and doxycycline with mean 
of 1.47days (p value 0.602).  
The total inotrope requirement was higher in the combined group of doxycycline and 
azithromycin group with mean of 1.62days, compared to azithromycin with mean of 
1.47 days (p value 0.276). 
The total oxygen requirement was lower in azithromycin group with a mean of 
4.93days, compared to doxycycline and the combined group of doxycycline and 
azithromycin with a mean of 5.50 days and 5.54 days respectively (p value 0.872). 
The non invasive ventilation (NIV) requirement was longer in doxycycline group with 
a mean of 3.50 days, compared to azithromycin and the combined group of 
azithromycin and doxycycline group , mean of 0.67 days and 0.67 days (p value 
0.556). The total days of invasive ventilation (IV) was longer in the combined group 
of doxycycline and azithromycin with a mean of 4.64 days, compared to doxycycline 
group with mean of 2 days and azithromycin group with mean of 3.73 days (p value 
0.486). The sensorium recovery was faster in azithromycin group with a mean of 3.53 
days (p value 0.439). (Table 23) 
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DISCUSSION 
 
Scrub typhus is a common cause of acute febrile illness in the tsutsugamushi triangle, 
is caused by a rickettsial organism Orientia tsutsugamushi. In this cohort 241 patients 
were screened and 223 satisfied the inclusion criteria, the incidence of delayed 
defervescence was highest in this study (24.66%) compared to previous studies. 
The mean age of 47.6 ± 15.1 years was comparable to studies from  South India, mean 
age (40-46 years)(4,8,41,46,84). Females were more commonly affected than men, 
which was similar to studies done by Kim et al and Griffith et al (7,7,41). However 
male predominance was seen in studies from South India(4,46). There is a change in 
trend towards female predominance which could have been because of increasing 
number of women working in the fields. Scrub typhus usually occurs in the 
occupations which have an increased exposure to the scrub vegetation and around 
houses. Studies from our institution had shown housewives to be the predominant 
occupation which was also seen in our cohort, the other professions being farmers , 
manual labourer.(46)   
The mean duration of illness depends on the time taken by the subjects to seek 
medical attention and also the incubation period,  it was 8.33 days in our study which 
was similar to studies done in the same geographic areas of south India (mean 8-
8.5days)(4,41).  
The eschar which is a characteristic feature of scrub typhus indicates initial site of 
inoculation by the chigger through which the organism enters the lymphatic and 
systemic dissemination, thus forming an important diagnostic feature(85). The eschar 
detection rate is very variable ranging from 37.6-55% (4,4,41,46,84). The detection 
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rate of 72.2% in this study was one of the highest in the country. This may have been 
because of increasing awareness of the disease and vigilance in searching for this vital 
diagnostic feature. The detection rates are very high in the orient (Japan and Korea) 
which may be due to the  racial differences in the skin colour aiding in easy 
identification(86,87). 
Scrub typhus commonly causes multiorgan dysfunction leading to high rates of 
mortality if not treated. The respiratory system is predominantly involved with very 
high incidence(68.5%-73.5%) (4,41). The pathogenesis is most probably because of 
interstitial pneumonia with or without vasculitis(38). In our cohort, though 
breathlessness (88.3%) was the common presenting symptom, respiratory dysfunction 
requiring oxygen was seen in about half of the subjects (50%). This emphasizes the 
fact that patients presenting with acute undifferentiated febrile illness with respiratory 
dysfunction increases the probability of scrub typhus in this geographic area. CNS 
dysfunction is seen in the form of meningoencephalitis, encephalomyelitis or focal 
neurological deficits, with altered sensorium being the most common presenting 
feature (22-32%) (46). In our cohort critically ill subjects had higher involvement of 
the CNS.   
Thrombocytopenia is a characteristic laboratory feature and can be seen in very high 
proportion of subjects. It is caused secondary to localized and generalized vasculitis. 
(4, 41).In our study hematological system was commonly involved with a very high 
percentage of subjects having thrombocytopenia, with higher proportion in the 
critically ill subjects. Majority of our patients had leukocytosis. In a tropical country 
like India, dengue, an arboviral illness has similar presentation as scrub typhus and is 
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found in the same geographical areas. This often causes difficulty in diagnoses in the 
absence of protean manifestations of scrub typhus. Presence of leukocytosis with 
multiorgan dysfunction may help in considering scrub typhus as a diagnostic 
possibility.  
Hepatic dysfunction in the form of transaminitis is a very consistent finding (60-90%) 
in the majority of the subjects in several of the studies. (46, 47) The patients in the 
critically ill group had more liver dysfunction, indicating liver is a prime target in 
severe scrub typhus. We noted that hepatocellular pattern of injury in the form of 
enzyme elevation was the predominant type of liver injury. 
Renal dysfunction ranges from acute renal failure requiring dialysis to microscopic 
proteinuria and pyuria. It is seen in a variable proportion (18-30%) of subjects with 
increased involvement in critically ill subjects (68.3%) (4,21,41,42). In our study we 
noticed that renal dysfunction was common (20.6%) and was comparable to earlier 
studies with an obviously higher percentage in the critically ill patients. 
Hypoalbuminemia is a common finding in scrub typhus, which is caused due to 
cytokine and cytotoxic damage leading to vascular leakage. Lower albumin has been 
used as a predictor of mortality in scrub typhus(7)(48). In this cohort also lower 
albumin levels were seen in majority of subjects, indicating severity of illness at 
presentation and diffuse systemic involvement of the disease.  
Rapid fever defervescence after initial antibiotic therapy is considered a characteristic 
feature of scrub typhus with a delay in defervescence usually suggestive of an 
alternate diagnosis. The  incidence of delayed defervescence was only about 10% in a 
study done on US servicemen during Vietnam War with a mean duration of fever 
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being 27.8hours,  which was similar to study by Brown et  al from Malaysia (88,89). 
However studies in the last two decades showed an increase in the incidence of 
delayed defervescence following antimicrobial therapy which ranged from 18.4%-
21.5%(7,8). This delay in defervescence had been postulated to be due to infection 
with doxycycline resistant strains, more virulent strains or inadequate drug levels 
(7,8). A study from northern Thailand in 1996 had detected doxycycline resistant 
strains in the cell culture that could be due to be an increased selection of resistant 
strains in the mite chiggers(90). However in vivo resistance has never been proven.  
We hypothesized that the delay in defervescence is due to severity of illness and not 
due to pathogen factors. 
Our incidence of delayed defervescence (24.66%) was the highest ever reported. It 
was seen that the odds of patients with multiorgan involvement (more than 2 organs) 
having delayed defervescence was 14.6 times compared to those with less than one 
organ involvement. Respiratory system involvement was found to the independent 
predictor of delayed defervescence. Thus in this cohort severity of organ dysfunction 
was the likely determinant of increased defervescence time. Choice of antimicrobial 
therapy did not seem to affect the defervescence time.  
Most patients on monotherapy with doxycycline had single organ involvement and 
hence had lower rates of delayed defervescence as compared to dual therapy where 
majority had multiple organ involvement (15% v/s 28.1%).  
The combined severity of illness was assessed using SOFA score which is a combined 
scoring system, the SOFA score has never been studied in scrub typhus till now. The 
combined antibiotic group had higher SOFA (8.26) compared to the monotherapy 
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groups. In the critically ill subjects also the mean SOFA score (13.81) was higher in 
the combined antibiotic group. This denotes that combined therapy was preferred in 
the more severely ill subjects by the treating physicians. This uneven distribution may 
have resulted due to the selection bias that could have occurred in this study design. 
Scrub typhus affects multiple organs leading to dysfunction and failure and if left 
untreated mortality is seen in considerable proportion of subjects. This is the first 
prospective study that looked at the organ recovery following antimicrobial therapy. 
In this cohort the organ recovery appeared to be shorter in the doxycycline group 
compared to the other two antibiotic groups with respect to total hospital stay, 
inotrope requirement, oxygen requirement, ventilator requirement, CNS, renal 
dysfunction and hepatic dysfunction recovery. Thus the treatment with doxycycline as 
monotherapy was apparently better than the other two groups; however there could 
have been a selection bias with respect to severely ill subjects receiving combined 
therapy. Therefore further prospective randomized studies would be required to study 
the organ recovery with respect to different antibiotics. 
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CONCLUSIONS OF THE STUDY 
 
 The incidence of delayed defervescence was 24.66%, with the incidence in 
doxycycline group being 15.9%, and in azithromycin and the combined groups 
(azithromycin and doxycycline) being 28.1% and 28.1% respectively. The 
incidence of delayed defervescence in critically ill subjects was 28.6%.  
 Respiratory system dysfunction and the multiorgan involvement (more than two 
organs) independently predicted delayed defervescence.  
 Severity of organ dysfunction seems to determine the defervescence time rather 
than the choice of the antimicrobial therapy as postulated before.  
 Further prospective randomized studies are required with regard to this and also to 
develop newer antibiotics to combat this curable rickettsial infection.   
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LIMITATIONS OF THE STUDY 
 
1. This was an observational cohort study with no randomization of the antibiotic 
regimens used, leading to uneven distribution in the three groups. 
2. The follow up period was set as 2 weeks, new symptoms recruited after discharge 
could have been missed. 
3. Scrub IgM ELISA and or presence of eschar were used as a diagnostic criterion. 
However the gold standard for serological diagnosis is indirect fluorescent 
antibody (IFA) which was not available in our Institute.  But prior studies have 
validated IgM ELISA in our laboratory and pretest probability that a febrile illness 
with multiorgan involvement is scrub typhus is very high in our region.  
4. This being a tertiary referral care hospital, the profile could not be representative 
of the exact profile in the community. 
5. The pre hospital antibiotic administration to the subjects could not be precisely 
determined, which could have had a confounding effect on the result. This was 
minimized by doing a thorough clinical evaluation.  
6. Adequacy of antibiotics by checking the antibiotic levels in the blood was not 
done, which could have determined the pharmacokinetics of the drugs used.  
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ANNEXURE 1 
 
PATIENT INFORMATION SHEET 
 
 
Scrub typhus is an infective disease that is caused by an organism called Rickettsia and is 
spread by the bite of a mite while walking in grasslands or forest. It usually causes a short 
duration fever which recovers after taking a short course of antibiotics, sometimes it causes a 
very serious illness affecting the lungs, brain, and blood, liver and can cause death if not 
treated adequately. Hence starting treatment with antibiotics early is very important.  
 
This study is aimed at studying the pattern of illness with scrub typhus. The time taken for the 
disease to recover after starting the antibiotics will be studied. The effects of various 
antibiotics used in scrub typhus and their effects will be studied. This will help us compare 
the different antibiotics used and chose the best one in the treatment of this disease.  
 
By participating in the study you will not be made to incur any added expenses apart from the 
routine initial investigations. There will be no added risk or discomfort or discomfort of any 
kind to you by participating in this study. Any personal information that is collected as a part 
of this study will be maintained strictly confidential. Participation is entirely voluntary and 
refusal to participate will not involve any loss of benefit or change that treatment that you 
receive.  
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ANNEXURE 2 
 
PATIENT CONSENT FORM 
 
 
 
I have been explained about the details of the study- “Prospective observational study 
to determine the factors associated with outcome of scrub typhus (DDS Study).”, and I 
have also read the above information sheet and have understood the same. I hereby 
give my consent to participate in this study and my participation is voluntary.  
 
 
 
 
 
 
 
 
 
Study number:  
 
 
 
 
 
 
Subject’s name:                                             Hospital number:  
 
 
 
 
 
 
 
Subject’s signature/Thumb impression Investigators signature 
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Annexure 3- Data Abstraction sheet 
 Name:                                                 Age:           Sex: M / F     DOA/1st visit: …. /… /2012 
 
Hosp No:                                   Occupation: HW/Man labour/Student/Business/Farmer/…... 
State: TN/AP/WB/…………….                 Unit: OPD / Med 1 / Med 2 /Med 3/ Med 4 
Contact Number:                                        Address: 
                                                                     Village/ town:                            
Dur of fever        days  Seizures Yes / No No risk fac Other- 
Chills Yes / No Abd pain Yes / No DM Yes/no 
Gen myalgia  Yes / No Cough Yes / No HTN Yes/no 
Head ache Yes / No Breathless Yes / No CVA Yes/no 
Vomiting Yes / No RED Urine out Yes / No CLD Yes/no 
Overt bleed Yes/no Site:    Altered sensor Yes / No IHD Yes/no 
Smoker/alcoholic           / Pregnancy  CKD Yes/No 
 
Pulse            /min Crepitations Yes/no 
BP      /   mm Hg             MAP splenomegaly Yes/no 
Resp rate           /min Hepatomegaly Yes/no 
SPO2            % Rash Yes/no 
Eschar Yes/no     Site: Groin/Axilla/  
 
 
Haemoglobin   Creatinine/urea         / Bicarbonate  
TC  TB/DB        /   
Neutrophils                % Protein/Albumin        /   
Lymphocytes                % SGOT/SGPT        /   
Platelets                                           ALP           
 
SOFA(SF)         0       1        2             3               4 (SF 1) SF2 SF3 
P/F ratio >400 ≤400 ≤300 ≤200 ≤100    
Platelets >1.5L 1-1.5  L 50-1 L 20,000-50,000 <20000 
Bilirubin <1.2 1.2-1.9 2-5.9 6-11.9 >12 
BP No hypo map<70 D<5  D>5/Ad<0.1 D>15/Adr>0.1 
GCS 15 13-14 10-12 6-9 <6 
Creat <1.2 1.2-1.9 2-3.4 3.5-4.9 >5 
 
 Initiation    Fever defervescence 
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 Date  Time  Duration  Date  Time  Defer time 
Doxy    days    
Azithro   days    
Doxy+ Azithro   days    
Others        
 
Antipyretics   Steroids   
Dose /dur  Drug   
Frequency  Prn/tid/bd Dose /dur  
Indication   Frequency   
 
 
 
 
 
 
 
 
OP / IP If IP: MICU / I / C / E / MTS4 / Isolation / Private 
Dur of adm MICU/MHDU            days Ward             days Total        days 
Supports  NIV/IV Oxygen  Inotropes    Dialysis(No) 
Duration       /       Total  Ad/NA/D/V             days                 
Outcome at dis Alive / Dead Stat at dis Afebrile / Fever persisting  
 Cardiovascular  Respiratory  Central nervous  Renal  Liver  
 BP Inotropes Oxygen P/F GCS Sensorium Creat  output TB SGOT/SGPT 
Day1 N/Hypo 1/2/3/4         
Day2 N/Hypo 1/2/3/4         
Day3 N/Hypo 1/2/3/4         
Day4 N/Hypo 1/2/3/4         
Day5 N/Hypo 1/2/3/4         
Day6 N/Hypo 1/2/3/4         
Day7 N/Hypo 1/2/3/4         
Day8 N/Hypo 1/2/3/4         
Day9 N/Hypo 1/2/3/4         
Day10 N/Hypo 1/2/3/4         
Day11 N/Hypo 1/2/3/4         
Day12 N/Hypo 1/2/3/4         
Day13 N/Hypo 1/2/3/4         
Day14 N/Hypo 1/2/3/4         
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Sequential organ failure assessement(SOFA) Score 
Adapted from- The SOFA (Sepsis-related Organ Failure Assessment) score to 
describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-
Related Problems of the European Society of Intensive Care Medicine Vincent 
JL et al, Intensive Care Med 1996 Jul;22(7):707-10. 
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Annexure 4-Data sheet 
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